Targeting cancer-associated glycans as a therapeutic strategy in leukemia

References

• Agrawal P, Nawadkar R, Ojha H, Kumar J, Sahu A. 2017. Complement evasion strategies of viruses: an overview. Front Microbiol. 8:1117. doi:10.3389/fmicb.2017.01117.
   PubMed Web of Science ®Google Scholar
• Ailles LE, Weissman IL. 2007. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 18(5):460–466. doi:10.1016/j.copbio.2007.10.007.
   PubMed Web of Science ®Google Scholar
• Akella NM, Ciraku L, Reginato MJ. 2019. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol. 17(1):52. doi:10.1186/s12915-019-0671-3.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Song J, Stiller T. 2017. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 92(9):858–865. doi:10.1002/ajh.24783.
   PubMed Web of Science ®Google Scholar
• Alfonso S, Valdés-Zayas A, Santiesteban ER. 2014. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 20(14):3660–3671. doi:10.1158/1078-0432.CCR-13-1674.
   PubMed Web of Science ®Google Scholar
• Ali YM, Lynch NJ, Haleem KS. 2012. The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog. 8(7):e1002793. doi:10.1371/journal.ppat.1002793.
   PubMed Web of Science ®Google Scholar
• Aller CT, Kucuk O, Springer GF, Gilman-Sachs A. 1996. Flow cytometric analysis of T and Tn epitopes on chronic lymphocytic leukemia cells. Am J Hematol. 52(1):29–38. doi:10.1002/(SICI)1096-8652(199605)52:1<29::AID-AJH5>3.0.CO;2-8.
   PubMed Web of Science ®Google Scholar
• Alvarez-Rueda N, Desselle A, Cochonneau D. 2011. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS One. 6(9):e25220. doi:10.1371/journal.pone.0025220.
   PubMed Web of Science ®Google Scholar
• Amado M, Carneiro F, Seixas M, Clausen H, Sobrinho-Simões M. 1998. Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology. 114(3):462–470. doi:10.1016/s0016-5085(98)70529-3.
   PubMed Web of Science ®Google Scholar
• An HJ, Kronewitter SR, de Leoz ML, Lebrilla CB. 2009. Glycomics and disease markers. Curr Opin Chem Biol. 13(5-6):601–607. doi:10.1016/j.cbpa.2009.08.015.
   PubMed Web of Science ®Google Scholar
• Anguille S, Van Tendeloo VF, Berneman ZN. 2012. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 26(10):2186–2196. doi:10.1038/leu.2012.145.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Yuriev E, Ramsland PA. 2003. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA. 100(25):15029–15034. doi:10.1073/pnas.2432220100.
   PubMed Web of Science ®Google Scholar
• Apweiler R, Hermjakob H, Sharon N. 1999. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta. 1473(1):4–8. doi:10.1016/s0304-4165(99)00165-8.
   PubMed Web of Science ®Google Scholar
• Arnaud J, Audfray A, Imberty A. 2013. Binding sugars: from natural lectins to synthetic receptors and engineered neolectins. Chem Soc Rev. 42(11):4798–4813. doi:10.1039/c2cs35435g.
   PubMed Web of Science ®Google Scholar
• Asano S, Pal R, Tanaka HN. 2019. Development of fluorescently labeled SSEA-3, SSEA-4, and Globo-H glycosphingolipids for elucidating molecular interactions in the cell membrane. Int J Mol Sci. 20(24):6187. doi:10.3390/ijms20246187.
   PubMed Web of Science ®Google Scholar
• Asiry S, Kim G, Filippou PS. 2021. The cancer cell dissemination machinery as an immunosuppressive niche: a new obstacle towards the era of cancer immunotherapy. Front Immunol. 12:654877. doi:10.3389/fimmu.2021.654877.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J. 2017. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 376(5):429–439. doi:10.1056/NEJMoa1611770.
   PubMed Web of Science ®Google Scholar
• Auslander N, Cunningham CE, Toosi BM. 2017. An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer. Mol Syst Biol. 13(12):956. doi:10.15252/msb.20177739.
   PubMed Web of Science ®Google Scholar
• Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. 2004. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol. 173:6841–6849. doi:10.4049/jimmunol.173.11.6841.
   PubMed Web of Science ®Google Scholar
• Azizidoost S, Vijay V, Cogle CR, Khodadi E, Saki N. 2017. The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia. Clin Transl Oncol. 19(9):1059–1066. doi:10.1007/s12094-017-1642-1.
   PubMed Web of Science ®Google Scholar
• Badar T, Szabo A, Litzow M. 2021. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 56(8):1998–2004. doi:10.1038/s41409-021-01279-w.
   PubMed Web of Science ®Google Scholar
• Bajwa R, Schechter T, Soni S. 2013. Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplant. 48(5):661–665. doi:10.1038/bmt.2012.209.
   PubMed Web of Science ®Google Scholar
• Baldus SE, Zirbes TK, Mönig SP. 1998. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: sialosyl-Lewis(a), Sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol. 19(6):445–453. doi:10.1159/000030036.
   PubMedGoogle Scholar
• Ballehaninna UK, Chamberlain RS. 2012. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 3(2):105–119. doi:10.3978/j.issn.2078-6891.2011.021.
   PubMedGoogle Scholar
• Balzarini J. 2007a. Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? Antivir Chem Chemother. 18(1):1–11. doi:10.1177/095632020701800101.
   PubMedGoogle Scholar
• Balzarini J. 2007b. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol. 5(8):583–597. doi:10.1038/nrmicro1707.
   PubMed Web of Science ®Google Scholar
• Barbier V, Erbani J, Fiveash C. 2020. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat Commun. 11(1):2042. doi:10.1038/s41467-020-15817-5.
   PubMed Web of Science ®Google Scholar
• Beatson R, Tajadura-Ortega V, Achkova D. 2016. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 17(11):1273–1281. doi:10.1038/ni.3552.
   PubMed Web of Science ®Google Scholar
• Bednar KJ, Shanina E, Ballet R. 2017. Human CD22 inhibits murine B cell receptor activation in a human CD22 transgenic mouse model. J Immunol. 199(9):3116–3128. doi:10.4049/jimmunol.1700898.
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Weisdorf DJ, Logan BR. 2015. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 21(3):454–459. doi:10.1016/j.bbmt.2014.11.007.
   PubMed Web of Science ®Google Scholar
• Belardi B, Bertozzi CR. 2015. Chemical lectinology: tools for probing the ligands and dynamics of mammalian lectins in vivo. Chem Biol. 22(8):983–993. doi:10.1016/j.chembiol.2015.07.009.
   PubMedGoogle Scholar
• Belisle JA, Gubbels JA, Raphael CA. 2007. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology. 122(3):418–429. doi:10.1111/j.1365-2567.2007.02660.x.
   PubMed Web of Science ®Google Scholar
• Bellone S, Roque D, Cocco E. 2012. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br J Cancer. 106(9):1543–1550. doi:10.1038/bjc.2012.132.
   PubMed Web of Science ®Google Scholar
• Bergfeld AK, Pearce OM, Diaz SL, Pham T, Varki A. 2012. Metabolism of vertebrate amino sugars with N-glycolyl groups: elucidating the intracellular fate of the non-human sialic acid N-glycolylneuraminic acid. J Biol Chem. 287(34):28865–28881. doi:10.1074/jbc.M112.363549.
   PubMed Web of Science ®Google Scholar
• Bertuzzi S, Quintana JI, Ardá A, Gimeno A, Jiménez-Barbero J. 2020. Targeting galectins with glycomimetics. Front Chem. 8:593. doi:10.3389/fchem.2020.00593.
   PubMed Web of Science ®Google Scholar
• Beyer-Sehlmeyer G, Hiddemann W, Wörmann B, Bertram J. 1999. Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin. Eur J Cancer. 35(12):1735–1742. doi:10.1016/s0959-8049(99)00202-6.
   PubMed Web of Science ®Google Scholar
• Bhatia R, Gautam SK, Cannon A. 2019. Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev. 38(1-2):223–236. doi:10.1007/s10555-018-09775-0.
   PubMed Web of Science ®Google Scholar
• Birks SM, Danquah JO, King L, Vlasak R, Gorecki DC, Pilkington GJ. 2011. Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. Neuro Oncol. 13(9):950–960. doi:10.1093/neuonc/nor108.
   PubMed Web of Science ®Google Scholar
• Blaeschke F, Willier S, Stenger D. 2020. Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. Leukemia. 34(10):2607–2620. doi:10.1038/s41375-020-0793-1.
   PubMed Web of Science ®Google Scholar
• Blsakova A, Kveton F, Kasak P, Tkac J. 2019. Antibodies against aberrant glycans as cancer biomarkers. Expert Rev Mol Diagn. 19(12):1057–1068. doi:10.1080/14737159.2020.1687295.
   PubMed Web of Science ®Google Scholar
• Bochner BS, Zimmermann N. 2015. Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation. J Allergy Clin Immunol. 135(3):598–608. doi:10.1016/j.jaci.2014.11.031.
   PubMed Web of Science ®Google Scholar
• Bornhöfft KF, Goldammer T, Rebl A, Galuska SP. 2018. Siglecs: a journey through the evolution of sialic acid-binding immunoglobulin-type lectins. Dev Comp Immunol. 86:219–231. doi:10.1016/j.dci.2018.05.008.
   PubMed Web of Science ®Google Scholar
• Boroughs LK, DeBerardinis RJ. 2015. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 17(4):351–359. doi:10.1038/ncb3124.
   PubMed Web of Science ®Google Scholar
• Bottoni P, Scatena R. 2015. The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol. 867:229–244. doi:10.1007/978-94-017-7215-0_14.
   PubMed Web of Science ®Google Scholar
• Bowles WHD, Gloster TM. 2021. Sialidase and sialyltransferase inhibitors: targeting pathogenicity and disease. Front Mol Biosci. 8:705133. doi:10.3389/fmolb.2021.705133.
   PubMed Web of Science ®Google Scholar
• Brändlein S, Pohle T, Ruoff N, Wozniak E, Müller-Hermelink HK, Vollmers HP. 2003. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 63(22):7995–8005.
   PubMed Web of Science ®Google Scholar
• Bremer EG, Levery SB, Sonnino S. 1984. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem. 259(23):14773–14777.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Niv Y, Byrd JC. 1991. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest. 87(3):1037–1045. doi:10.1172/JCI115063.
   PubMed Web of Science ®Google Scholar
• Bride KL, Vincent TL, Im SY. 2018. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 131(9):995–999. doi:10.1182/blood-2017-07-794214.
   PubMed Web of Science ®Google Scholar
• Brockhausen I. 2003. Glycodynamics of mucin biosynthesis in gastrointestinal tumor cells. Adv Exp Med Biol. 535:163–188. doi:10.1007/978-1-4615-0065-0_11.
   PubMed Web of Science ®Google Scholar
• Brockhausen I, Stanley P. 2017. O-GalNAc glycans. In: Varki A, Cummings RD, Esko JD, editor. Essentials of glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; p. 2015–2017. https://www.ncbi.nlm.nih.gov/books/NBK453030/ doi: 10.1101/glycobiology.3e.010.
   Google Scholar
• Brodsky RA. 2014. Paroxysmal nocturnal hemoglobinuria. Blood. 124(18):2804–2811. doi:10.1182/blood-2014-02-522128.
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P. 2001. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61(18):6846–6850.
   PubMed Web of Science ®Google Scholar
• Brown PA, Ji L, Xu X. 2021. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 325(9):833–842. doi:10.1001/jama.2021.0669.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Walter RB. 2015. Antigen-specific immunotherapies for acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2015:584–595. doi:10.1182/asheducation-2015.1.584.
   PubMedGoogle Scholar
• Büll C, Boltje TJ, Balneger N. 2018. Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity. Cancer Res. 78(13):3574–3588. doi:10.1158/0008-5472.CAN-17-3376.
   PubMed Web of Science ®Google Scholar
• Büll C, Stoel MA, den Brok MH, Adema GJ. 2014. Sialic acids sweeten a tumor’s life. Cancer Res. 74(12):3199–3204. doi:10.1158/0008-5472.CAN-14-0728.
   PubMed Web of Science ®Google Scholar
• Burchell J, Poulsom R, Hanby A. 1999. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology. 9(12):1307–1311. doi:10.1093/glycob/9.12.1307.
   PubMed Web of Science ®Google Scholar
• Cagnoni AJ, Pérez Sáez JM, Rabinovich GA, Mariño KV. 2016. Turning-off signaling by siglecs, selectins, and galectins: chemical inhibition of glycan-dependent interactions in cancer. Front Oncol. 6:109. doi:10.3389/fonc.2016.00109.
   PubMed Web of Science ®Google Scholar
• Camby I, Le Mercier M, Lefranc F, Kiss R. 2006. Galectin-1: a small protein with major functions. Glycobiology. 16(11):137R–157R. doi:10.1093/glycob/cwl025.
   PubMed Web of Science ®Google Scholar
• Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. 2009. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood. 113(14):3333–3336. doi:10.1182/blood-2008-11-187302.
   PubMed Web of Science ®Google Scholar
• Carr A, Rodríguez E, Arango Mdel C. 2003. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol. 21(6):1015–1021. doi:10.1200/JCO.2003.02.124.
   PubMed Web of Science ®Google Scholar
• Carroll MV, Sim RB. 2011. Complement in health and disease. Adv Drug Deliv Rev. 63(12):965–975. doi:10.1016/j.addr.2011.06.005.
   PubMed Web of Science ®Google Scholar
• Carter JL, Hege K, Yang J. 2020. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 5(1):288. doi:10.1038/s41392-020-00361-x.
   PubMed Web of Science ®Google Scholar
• Caruana I, Diaconu I, Dotti G. 2014. From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. Semin Oncol. 41(5):661–666. doi:10.1053/j.seminoncol.2014.08.005.
   PubMed Web of Science ®Google Scholar
• Carvalho FC, Soares SG, Tamarozzi MB, Rego EM, Roque-Barreira MC. 2011. The recognition of N-glycans by the lectin ArtinM mediates cell death of a human myeloid leukemia cell line. PLoS One. 6(11):e27892. doi:10.1371/journal.pone.0027892.
   PubMed Web of Science ®Google Scholar
• Cavdarli S, Dewald JH, Yamakawa N. 2019. Identification of 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac2) as main O-acetylated sialic acid species of GD2 in breast cancer cells. Glycoconj J. 36(1):79–90. doi:10.1007/s10719-018-09856-w.
   PubMed Web of Science ®Google Scholar
• Cavdarli S, Schröter L, Albers M. 2021. Role of sialyl-O-acetyltransferase CASD1 on GD2 ganglioside O-acetylation in breast cancer cells. Cells. 10(6):1468. doi:10.3390/cells10061468.
   PubMed Web of Science ®Google Scholar
• Cedzyński M, Świerzko AS. 2020. Components of the lectin pathway of complement in haematologic malignancies. Cancers. 12(7):1792. doi:10.3390/cancers12071792.
   PubMed Web of Science ®Google Scholar
•  Cell Adhesion and the Extracellular Matrix. 2021. Goodman’s medical cell biology. p. 203–247. doi:10.1016/b978-0-12-817927-7.00007-7.
   Google Scholar
• Cerliani JP, Stowell SR, Mascanfroni ID, Arthur CM, Cummings RD, Rabinovich GA. 2011. Expanding the universe of cytokines and pattern recognition receptors: galectins and glycans in innate immunity. J Clin Immunol. 31(1):10–21. doi:10.1007/s10875-010-9494-2.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Dorsett KA, Trummell HQ. 2018. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem. 293(3):984–994. doi:10.1074/jbc.M117.808584.
   PubMed Web of Science ®Google Scholar
• Chang WC, Hartshorn KL, White MR. 2011. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem Pharmacol. 81(3):388–395. doi:10.1016/j.bcp.2010.10.012.
   PubMed Web of Science ®Google Scholar
• Chang YC, Nizet V. 2014. The interplay between Siglecs and sialylated pathogens. Glycobiology. 24(9):818–825. doi:10.1093/glycob/cwu067.
   PubMed Web of Science ®Google Scholar
• Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. 2020. CA125 and ovarian cancer: a comprehensive review. Cancers. 12(12):3730. doi:10.3390/cancers12123730.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS. 2009. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 15(17):5323–5337. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Chen CY, Jan YH, Juan YH. 2013. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci USA. 110(2):630–635. doi:10.1073/pnas.1220425110.
   PubMed Web of Science ®Google Scholar
• Chen J, Glasser CL. 2020. New and emerging targeted therapies for pediatric acute myeloid leukemia (AML). Children. 7(2):12. doi:10.3390/children7020012.
   PubMedGoogle Scholar
• Chen L, Zhang W, Fregien N, Pierce M. 1998. The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. Oncogene. 17(16):2087–2093. doi:10.1038/sj.onc.1202124.
   PubMed Web of Science ®Google Scholar
• Cheng CL, Hou HA, Lee MC. 2013. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood. 121(16):3172–3180. doi:10.1182/blood-2012-07-443762.
   PubMed Web of Science ®Google Scholar
• Cheung LS-L, Raman PS, Wirtz D, Konstantopoulos K. 2012. Biophysics of selectin-mediated cell adhesion. In: Edward H. Egelman, editor. Comprehensive biophysics. Elsevier; p. 10–32. doi:10.1016/B978-0-12-374920-8.00703-7
   Google Scholar
• Cho RW, Clarke MF. 2008. Recent advances in cancer stem cells. Curr Opin Genet Dev. 18(1):48–53. doi:10.1016/j.gde.2008.01.017.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Bandyopadhyay S, Mandal C, Chandra S, Mandal C. 2008. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study. BMC Cancer. 8:40. doi:10.1186/1471-2407-8-40.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Mandal C. 2009. O-acetylated sialic acids: multifaceted role in childhood acute lymphoblastic leukaemia. Biotechnol J. 4(3):361–374. doi:10.1002/biot.200800253.
   PubMedGoogle Scholar
• Christiansen D, Vaughan HA, Milland J. 2011. Antibody responses to glycolipid-borne carbohydrates require CD4+ T cells but not CD1 or NKT cells [published correction appears in Immunol Cell Biol. 2011 May;89(4):574. Miland, Julie [corrected to Milland, Julie]. Immunol Cell Biol. 89(4):502–510. doi:10.1038/icb.2010.166.
   PubMed Web of Science ®Google Scholar
• Chua JX, Durrant L. 2017. Monoclonal antibodies against tumour-associated carbohydrate antigens, carbohydrate, Mahmut Caliskan, I. Halil Kavakli and Gul Cevahir Oz, IntechOpen, doi:10.5772/66996. https://www.intechopen.com/chapters/53645.
   Google Scholar
• Cogle CR, Bosse RC, Brewer T. 2016. Acute myeloid leukemia in the vascular niche. Cancer Lett. 380(2):552–560. doi:10.1016/j.canlet.2015.05.007.
   PubMed Web of Science ®Google Scholar
• Cohen D. 2009. Complications: tracking down the data on oseltamivir [published correction appears in BMJ. 2010; 340:c406]. Br Med J. 339:b5387. doi:10.1136/bmj.b5387.
   PubMedGoogle Scholar
• Coley WB. 1893. The treatment of malignant tumors by repeated inoculations of erysipelas. Am J Med Sci. 105:487–510.
   Google Scholar
• Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. 2008. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 68(10):3803–3809. doi:10.1158/0008-5472.CAN-07-6389.
   PubMed Web of Science ®Google Scholar
• Cordo V, van der Zwet J, Canté-Barrett K, Pieters R, Meijerink J. 2021. T-cell acute lymphoblastic leukemia: A roadmap to targeted therapies. Blood Cancer Discov. 2:19–31.
   PubMedGoogle Scholar
• Costa AF, Campos D, Reis CA, Gomes C. 2020. Targeting glycosylation: a new road for cancer drug discovery. Trends Cancer. 6(9):757–766. doi:10.1016/j.trecan.2020.04.002.
   PubMed Web of Science ®Google Scholar
• Covés-Datson EM, Dyall J, DeWald LE. 2019. Inhibition of Ebola virus by a molecularly engineered banana lectin. PLoS Negl Trop Dis. 13(7):e0007595. doi:10.1371/journal.pntd.0007595.
   PubMed Web of Science ®Google Scholar
• Covés-Datson EM, King SR, Legendre M. 2020. A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo. Proc Natl Acad Sci USA. 117(4):2122–2132. doi:10.1073/pnas.1915152117.
   PubMed Web of Science ®Google Scholar
• Crespo HJ, Lau JT, Videira PA. 2013. Dendritic cells: a spot on sialic acid. Front Immunol. 4:491. doi:10.3389/fimmu.2013.00491.
   PubMed Web of Science ®Google Scholar
• Crocker PR, Paulson JC, Varki A. 2007. Siglecs and their roles in the immune system. Nat Rev Immunol. 7(4):255–266. doi:10.1038/nri2056.
   PubMed Web of Science ®Google Scholar
• Cummins KD, Gill S. 2019. Will CAR T cell therapy have a role in AML? Promises and pitfalls. Semin Hematol. 56(2):155–163. doi:10.1053/j.seminhematol.2018.08.008.
   PubMed Web of Science ®Google Scholar
• Curran E, Stock W. 2019. Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL. Blood. 133(16):1715–1719. doi:10.1182/blood-2018-12-852376.
   PubMed Web of Science ®Google Scholar
• D’Addio M, Frey J, Otto VI. 2020. The manifold roles of sialic acid for the biological functions of endothelial glycoproteins. Glycobiology. 30(8):490–499. doi:10.1093/glycob/cwaa008.
   PubMed Web of Science ®Google Scholar
• Daniotti JL, Vilcaes AA, Torres Demichelis V, Ruggiero FM, Rodriguez-Walker M. 2013. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol. 3:306. doi:10.3389/fonc.2013.00306.
   PubMedGoogle Scholar
• Daver N, Alotaibi AS, Bücklein V, Subklewe M. 2021. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 35(7):1843–1863. doi:10.1038/s41375-021-01253-x.
   PubMed Web of Science ®Google Scholar
• Davis AP. 2009. Synthetic lectins. Org Biomol Chem. 7(18):3629–3638. doi:10.1039/b909856a.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ. 2019. High E- selectin ligand expression contributes to chemotherapy-resistance in poor risk relapsed and refractory (R/R) acute myeloid leukemia (AML) patients and can be overcome with the addition of uproleselan. Blood. 134:2690.
   Web of Science ®Google Scholar
• DeAngelo DJ, Erba HP, Jonas BA. 2019. A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 37(Suppl. 15). doi:10.1200/JCO.2019.37.15_suppl.TPS7066
   Web of Science ®Google Scholar
• Decker WK, da Silva RF, Sanabria MH. 2017. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 8:829. doi:10.3389/fimmu.2017.00829.
   PubMed Web of Science ®Google Scholar
• Decker WK, Safdar A. 2009. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley’s legacy revisited. Cytokine Growth Factor Rev. 20(4):271–281. doi:10.1016/j.cytogfr.2009.07.004.
   PubMed Web of Science ®Google Scholar
• de Haan N, Wuhrer M, Ruhaak LR. 2020. Mass spectrometry in clinical glycomics: the path from biomarker identification to clinical implementation. Clin Mass Spectrom. 18:1–12. doi:10.1016/j.clinms.2020.08.001.
   PubMedGoogle Scholar
• Delaine T, Collins P, MacKinnon A. 2016. Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition. Chembiochem. 17(18):1759–1770. doi:10.1002/cbic.201600285.
   PubMed Web of Science ®Google Scholar
• Delcommenne M, Klingemann HG. 2012. Detection and characterization of syndecan-1-associated heparan sulfate 6-O-sulfated motifs overexpressed in multiple myeloma cells using single chain antibody variable fragments. Hum Antibodies. 21(1-2):29–40. doi:10.3233/HAB-2012-0259.
   PubMedGoogle Scholar
• Dennis JW, Laferté S, Waghorne C, Breitman ML, Kerbel RS. 1987. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science. 236(4801):582–585. doi:10.1126/science.2953071.
   PubMed Web of Science ®Google Scholar
• de Vries JF, Zwaan CM, De Bie M. 2012. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 26(2):255–264. doi:10.1038/leu.2011.206.
   PubMed Web of Science ®Google Scholar
• Dhar C, Sasmal A, Varki A. 2019. From “serum sickness” to “xenosialitis”: past, present, and future significance of the non-human sialic acid Neu5Gc. Front Immunol. 10:807. doi:10.3389/fimmu.2019.00807.
   PubMed Web of Science ®Google Scholar
• Diaz SL, Padler-Karavani V, Ghaderi D. 2009. Sensitive and specific detection of the non-human sialic acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS One. 4(1):e4241. doi:10.1371/journal.pone.0004241.
   PubMed Web of Science ®Google Scholar
• Dick JE. 2008. Stem cell concepts renew cancer research. Blood. 112(13):4793–4807. doi:10.1182/blood-2008-08-077941.
   PubMed Web of Science ®Google Scholar
• Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. 2007. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 21(11):2240–2245. doi:10.1038/sj.leu.2404866.
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK. 2011. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 67(4):741–749. doi:10.1007/s00280-010-1342-9.
   PubMed Web of Science ®Google Scholar
• Dinner S, Lee D, Liedtke M. 2014. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. Leuk Lymphoma. 55(8):1715–1724. doi:10.3109/10428194.2013.856428.
   PubMed Web of Science ®Google Scholar
• Diorio C, Teachey DT. 2020. Harnessing immunotherapy for pediatric T-cell malignancies. Expert Rev Clin Immunol. 16(4):361–371. doi:10.1080/1744666X.2020.1732819.
   PubMed Web of Science ®Google Scholar
• Dobie C, Skropeta D. 2021. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 124(1):76–90. doi:10.1038/s41416-020-01126-7.
   PubMed Web of Science ®Google Scholar
• Dolgin E. 2020. Immunotherapy takes aim at exhausted T cells. Nat Biotechnol. 38(1):3–5. doi:10.1038/s41587-019-0381-y.
   PubMed Web of Science ®Google Scholar
• Donati M, Brancato G, Donati A. 2010. Clinical biomarkers in hepatocellular carcinoma (HCC). Front Biosci. 2(2):571–577. doi:10.2741/s86.
   Google Scholar
• Drake RR, Schwegler EE, Malik G. 2006. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteom. 5(10):1957–1967. doi:10.1074/mcp.M600176-MCP200.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Shering S, Sherry F, McDermott E, O’Higgins N. 2000. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers. 15(4):330–333.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3(11):991–998. doi:10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. 2004a. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21(2):137–148. doi:10.1016/j.immuni.2004.07.017.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. 2004b. The three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360. doi:10.1146/annurev.immunol.22.012703.104803.
   PubMed Web of Science ®Google Scholar
• Durrant LG, Noble P, Spendlove I. 2012. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol. 167(2):206–215. doi:10.1111/j.1365-2249.2011.04516.x.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Kramer M, Röllig C. 2014. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 4(6):e218. doi:10.1038/bcj.2014.39.
   PubMed Web of Science ®Google Scholar
• Eisen S, Dzwonek A, Klein NJ. 2008. Mannose-binding lectin in HIV infection. Future Virol. 3(3):225–233. doi:10.2217/17460794.3.3.225.
   PubMed Web of Science ®Google Scholar
• Ernst B, Magnani JL. 2009. From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov. 8(8):661–677. doi:10.1038/nrd2852.
   PubMed Web of Science ®Google Scholar
• Esposito M, Mondal N, Greco TM. 2019. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nat Cell Biol. 21(5):627–639. doi:10.1038/s41556-019-0309-2.
   PubMed Web of Science ®Google Scholar
• Essers MA, Trumpp A. 2010. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 4(5):443–450. doi:10.1016/j.molonc.2010.06.001.
   PubMed Web of Science ®Google Scholar
• Faderl S, O’Brien S, Pui CH. 2010. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 116(5):1165–1176. doi:10.1002/cncr.24862.
   PubMed Web of Science ®Google Scholar
• Fahr C, Schauer R. 2001. Detection of sialic acids and gangliosides with special reference to 9-O-acetylated species in basaliomas and normal human skin. J Invest Dermatol. 116(2):254–260. doi:10.1046/j.1523-1747.2001.01237.x.
   PubMed Web of Science ®Google Scholar
• Farhad M, Rolig AS, Redmond WL. 2018. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 7(6):e1434467. doi:10.1080/2162402X.2018.1434467.
   PubMed Web of Science ®Google Scholar
• Feng D, Shaikh AS, Wang F. 2016a. Recent advance in tumor-associated carbohydrate antigens (TACAs)-based antitumor vaccines. ACS Chem Biol. 11(4):850–863. doi:10.1021/acschembio.6b00084.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhao L, Gao S. 2016b. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Gene. 578(2):232–241. doi:10.1016/j.gene.2015.12.028.
   PubMed Web of Science ®Google Scholar
• Ferens-Sieczkowska M, Kratz EM, Kossowska B, Passowicz-Muszyńska E, Jankowska R. 2013. Comparison of haptoglobin and alpha 1-acid glycoprotein glycosylation in the sera of small cell and non-small cell lung cancer patients. Postepy Hig Med Dosw. 67:828–836. doi:10.5604/17322693.1061788.
   Web of Science ®Google Scholar
• Ferguson MAJ, Hart GW, Kinoshita T. 2017. Glycosylphosphatidylinositol anchors. In: Varki A, Cummings RD, Esko JD, editor. Essentials of glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; p. 137–150.
   Google Scholar
• Fernandez-Poza S, Padros A, Thompson R. 2021. Tailor-made recombinant prokaryotic lectins for characterisation of glycoproteins. Anal Chim Acta. 1155:338352. doi:10.1016/j.aca.2021.338352.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J. 2016. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375(19):1856–1867. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Feucht J, Kayser S, Gorodezki D. 2016. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget. 7(47):76902–76919. doi:10.18632/oncotarget.12357.
   PubMed Web of Science ®Google Scholar
• Finn OJ. 2018. A believer’s overview of cancer immunosurveillance and immunotherapy. J Immunol. 200(2):385–391. doi:10.4049/jimmunol.1701302.
   PubMed Web of Science ®Google Scholar
• Fleischer LC, Spencer HT, Raikar SS. 2019. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 12(1):141. doi:10.1186/s13045-019-0801-y.
   PubMed Web of Science ®Google Scholar
• Flitsch SL. 2012. Enzymatic carbohydrate synthesis. In: Erick M. Carreira, Hisashi Yamamoto, editor. Comprehensive chirality. Elsevier; p. 454–464.
   Google Scholar
• Foster AJ, Bird JH, Timmer MSM, Stocker BL. 2015. The ligands of C-type lectins. C-type lectin receptors in immunity. 191–215. doi:10.1007/978-4-431-56015-9_13.
   Google Scholar
• François KO, Balzarini J. 2012. Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. Med Res Rev. 32(2):349–387. doi:10.1002/med.20216.
   PubMed Web of Science ®Google Scholar
• Freire T, Zhang X, Dériaud E. 2010. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. Blood. 116(18):3526–3536. doi:10.1182/blood-2010-04-279133.
   PubMed Web of Science ®Google Scholar
• Fujihara S, Mori H, Kobara H. 2013. Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov. 7(2):130–137. doi:10.2174/1872214811307020006.
   PubMedGoogle Scholar
• Fujita T, Matsushita M, Endo Y. 2004. The lectin-complement pathway – its role in innate immunity and evolution. Immunol Rev. 198:185–202. doi:10.1111/j.0105-2896.2004.0123.x.
   PubMed Web of Science ®Google Scholar
• Fuster MM, Esko JD. 2005. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 5(7):526–542. doi:10.1038/nrc1649.
   PubMed Web of Science ®Google Scholar
• Gabius HJ. 2013. The history of lectinology. In: Fang E., Ng T, editor. Antitumor potential and other emerging medicinal properties of natural compounds. Dordrecht: Springer. doi:10.1007/978-94-007-6214-5_2
   Google Scholar
• Gao L, Yu S, Zhang X. 2014. Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages. Cell Biochem Biophys. 70(1):273–277. doi:10.1007/s12013-014-9900-0.
   PubMed Web of Science ®Google Scholar
• Gardner A, Ruffell B. 2016. Dendritic cells and cancer immunity. Trends Immunol. 37(12):855–865. doi:10.1016/j.it.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Geis N, Zell S, Rutz R. 2010. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets. 10(8):922–931. doi:10.2174/156800910793357952.
   PubMed Web of Science ®Google Scholar
• Geller A, Yan J. 2019. The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy. Front Immunol. 10:1074. doi:10.3389/fimmu.2019.01074.
   PubMed Web of Science ®Google Scholar
• Gessner P, Riedl S, Quentmaier A, Kemmner W. 1993. Enhanced activity of CMP-neuAc:Gal beta 1-4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Lett. 75(3):143–149. doi:10.1016/0304-3835(93)90056-f.
   PubMed Web of Science ®Google Scholar
• Ghafoor D, Ahmed S, Zaman N. 2021. Lectins A hope of treatment for COVID-19. Am J Biomed Sci Res. doi:10.34297/AJBSR.2021.12.001757.
   Google Scholar
• Ghazarian H, Idoni B, Oppenheimer SB. 2011. A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem. 113(3):236–247. doi:10.1016/j.acthis.2010.02.004.
   PubMed Web of Science ®Google Scholar
• Ghosh S. 2020. Sialic acid and biology of life: an introduction. Sialic acids and sialoglycoconjugates in the biology of life, health and disease. p. 1–61. doi:10.1016/B978-0-12-816126-5.00001-9.
   Google Scholar
• Gianchecchi E, Delfino DV, Fierabracci A. 2013. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 12(11):1091–1100. doi:10.1016/j.autrev.2013.05.003.
   PubMed Web of Science ®Google Scholar
• Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. 2013. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome. J Invest Dermatol. 133(1):249–257. doi:10.1038/jid.2012.265.
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M. 2014. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells [published correction appears in blood. 2016 Nov 24;128(21):2585]. Blood. 123(15):2343–2354. doi:10.1182/blood-2013-09-529537.
   PubMed Web of Science ®Google Scholar
• Gion M, Mione R, Leon AE. 2001. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer. 37(3):355–363. doi:10.1016/s0959-8049(00)00396-8.
   PubMed Web of Science ®Google Scholar
• Glinsky VV, Glinsky GV, Rittenhouse-Olson K. 2001. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 61(12):4851–4857.
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 95(12):3900–3908.
   PubMed Web of Science ®Google Scholar
• Gomes C, Osório H, Pinto MT, Campos D, Oliveira MJ, Reis CA. 2013. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS One. 8(6):e66737. doi:10.1371/journal.pone.0066737.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gil A, Schnaar RL. 2021. Siglec ligands. Cells. 10(5):1260. doi:10.3390/cells10051260.
   PubMed Web of Science ®Google Scholar
• Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med. 6(3):306–312. doi:10.1038/73163.
   PubMed Web of Science ®Google Scholar
• Griffin ME, Hsieh-Wilson LC. 2016. Glycan engineering for cell and developmental biology. Cell Chem Biol. 23(1):108–121. doi:10.1016/j.chembiol.2015.12.007.
   PubMed Web of Science ®Google Scholar
• Gupta YK, Meenu M, Mohan P. 2015. The Tamiflu fiasco and lessons learnt. Indian J Pharmacol. 47(1):11–16. doi:10.4103/0253-7613.150308.
   PubMed Web of Science ®Google Scholar
• Hakomori S. 1989. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res. 52:257–331. doi:10.1016/s0065-230x(08)60215-8.
   PubMed Web of Science ®Google Scholar
• Hakomori S. 2001. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 491:369–402. doi:10.1007/978-1-4615-1267-7_24.
   PubMed Web of Science ®Google Scholar
• Hakomori S. 2002. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA. 99(16):10231–10233. doi:10.1073/pnas.172380699.
   PubMed Web of Science ®Google Scholar
• Haltalli MLR, Lo Celso C. 2020. Targeting adhesion to the vascular niche to improve therapy for acute myeloid leukemia. Nat Commun. 11(1):3691. doi:10.1038/s41467-020-17594-7.
   PubMed Web of Science ®Google Scholar
• Hamilton WB, Helling F, Lloyd KO, Livingston PO. 1993. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer. 53(4):566–573. doi:10.1002/ijc.2910530407.
   PubMed Web of Science ®Google Scholar
• Hanash SM, Pitteri SJ, Faca VM. 2008. Mining the plasma proteome for cancer biomarkers. Nature. 452(7187):571–579. doi:10.1038/nature06916.
   PubMed Web of Science ®Google Scholar
• Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. 2017. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine. 96(26):e7325. doi:10.1097/MD.0000000000007325.
   PubMed Web of Science ®Google Scholar
• Haubner S, Perna F, Köhnke T. 2019. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 33(1):64–74. doi:10.1038/s41375-018-0180-3.
   PubMed Web of Science ®Google Scholar
• He J, Liu Y, Xie X. 2010. Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach. J Proteome Res. 9(5):2565–2572. doi:10.1021/pr100012p.
   PubMed Web of Science ®Google Scholar
• Heijs B, Holst-Bernal S, de Graaff MA. 2020. Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging. Lab Invest. 100(9):1252–1261. doi:10.1038/s41374-020-0435-2.
   PubMed Web of Science ®Google Scholar
• Heise T, Langereis JD, Rossing E. 2018. Selective inhibition of sialic acid-based molecular mimicry in haemophilus influenzae abrogates serum resistance. Cell Chem Biol. 25(10):1279–1285. doi:10.1016/j.chembiol.2018.05.018.
   PubMed Web of Science ®Google Scholar
• Hellicar J, Stevenson NL, Stephens DJ, Lowe M. 2022. Supply chain logistics – the role of the Golgi complex in extracellular matrix production and maintenance. J Cell Sci. 135(1):jcs258879. doi:10.1242/jcs.258879.
   PubMed Web of Science ®Google Scholar
• Hendriks D, Choi G, de Bruyn M, Wiersma VR, Bremer E. 2017. Antibody-based cancer therapy: successful agents and novel approaches. Int Rev Cell Mol Biol. 331:289–383. doi:10.1016/bs.ircmb.2016.10.002.
   PubMed Web of Science ®Google Scholar
• Hevey R. 2019. Strategies for the development of glycomimetic drug candidates. Pharmaceuticals. 12(2):55. doi:10.3390/ph12020055.
   Web of Science ®Google Scholar
• Higashi H, Hirabayashi Y, Fukui Y. 1985. Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer. Cancer Res. 45(8):3796–3802.
   PubMed Web of Science ®Google Scholar
• Hira VVV, Van Noorden CJF, Carraway HE, Maciejewski JP, Molenaar RJ. 2017. Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. Biochim Biophys Acta Rev Cancer. 1868(1):183–198. doi:10.1016/j.bbcan.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Hirabayashi J, Arai R. 2019. Lectin engineering: the possible and the actual. Interface Focus. 9(2):20180068. doi:10.1098/rsfs.2018.0068.
   PubMed Web of Science ®Google Scholar
• Hiraiwa N, Yabuta T, Yoritomi K. 2003. Transactivation of the fucosyltransferase VII gene by human T-cell leukemia virus type 1 tax through a variant cAMP-responsive element. Blood. 101(9):3615–3621. doi:10.1182/blood-2002-07-2301.
   PubMed Web of Science ®Google Scholar
• Hitchcock CL, Povoski SP, Mojzisik CM, Martin EW. 2021. Survival advantage following TAG-72 antigen-directed cancer surgery in patients with colorectal carcinoma: proposed mechanisms of action. Front Oncol. 11:731350. doi:10.3389/fonc.2021.731350.
   PubMed Web of Science ®Google Scholar
• Ho TC, LaMere M, Stevens BM. 2016. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 128(13):1671–1678. doi:10.1182/blood-2016-02-695312.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Schoonmade LJ, Kaspers GJ. 2021. Pediatric relapsed acute myeloid leukemia: a systematic review. Expert Rev Anticancer Ther. 21(1):45–52. doi:10.1080/14737140.2021.1841640.
   PubMed Web of Science ®Google Scholar
• Hou S, Hang Q, Isaji T, Lu J, Fukuda T, Gu J. 2016. Importance of membrane-proximal N-glycosylation on integrin β1 in its activation and complex formation. FASEB J. 30(12):4120–4131. doi:10.1096/fj.201600665R.
   PubMed Web of Science ®Google Scholar
• Houvast RD, Vankemmelbeke M, Durrant LG. 2020. Targeting glycans and heavily glycosylated proteins for tumor imaging. Cancers. 12(12):3870. doi:10.3390/cancers12123870.
   PubMed Web of Science ®Google Scholar
• Hu D, Tateno H, Hirabayashi J. 2014. Directed evolution of lectins by an improved error-prone PCR and ribosome display method. Methods Mol Biol. 1200:527–538. doi:10.1007/978-1-4939-1292-6_43.
   PubMedGoogle Scholar
• Hu D, Tateno H, Hirabayashi J. 2015. Lectin engineering, a molecular evolutionary approach to expanding the lectin utilities. Molecules. 20(5):7637–7656. doi:10.3390/molecules20057637.
   PubMed Web of Science ®Google Scholar
• Huang S, Day TW, Choi MR, Safa AR. 2009. Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity. Mol Cell Biochem. 331(1-2):81–88. doi:10.1007/s11010-009-0147-9.
   PubMed Web of Science ®Google Scholar
• Hudak JE, Canham SM, Bertozzi CR. 2014. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 10(1):69–75. doi:10.1038/nchembio.1388.
   PubMed Web of Science ®Google Scholar
• Hussein NH, Amin NS, El Tayebi HM. 2020. GPI-AP: unraveling a new class of malignancy mediators and potential immunotherapy targets. Front Oncol. 10:537311. doi:10.3389/fonc.2020.537311.
   PubMed Web of Science ®Google Scholar
• Ibarlucea-Benitez I, Weitzenfeld P, Smith P, Ravetch JV. 2021. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc Natl Acad Sci USA. 118(26):e2107424118. doi:10.1073/pnas.2107424118.
   PubMed Web of Science ®Google Scholar
• Ishii K, Pouzolles M, Chien CD. 2020. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J Clin Invest. 130(10):5425–5443. doi:10.1172/JCI130059.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yoshida S, Saito Y. 2007. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 25(11):1315–1321. doi:10.1038/nbt1350.
   PubMed Web of Science ®Google Scholar
• Ito K, Ralph SJ. 2012. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence. Clin Exp Metastasis. 29(6):561–572. doi:10.1007/s10585-012-9471-7.
   PubMed Web of Science ®Google Scholar
• Itoh M, Kitano T, Watanabe M. 2003. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res. 9(1):415–423.
   PubMed Web of Science ®Google Scholar
• Jacob F, Goldstein DR, Bovin NV. 2012. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array. Int J Cancer. 130(1):138–146. doi:10.1002/ijc.26002.
   PubMed Web of Science ®Google Scholar
• Jacobson S, Larsson P, Åberg AM, Johansson G, Winsö O, Söderberg S. 2020. Levels of mannose-binding lectin (MBL) associates with sepsis-related in-hospital mortality in women. J Inflamm. 17:28. doi:10.1186/s12950-020-00257-1.
   Google Scholar
• Jacoby E. 2019. Relapse and resistance to CAR-T cells and blinatumomab in hematologic malignancies. Clin Hematol Int. 1:79–84.
   PubMedGoogle Scholar
• Jacoby E, Nguyen SM, Fountaine TJ. 2016. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 7:12320. doi:10.1038/ncomms12320.
   PubMed Web of Science ®Google Scholar
• Jain S, Stroopinsky D, Yin L. 2015. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 126(3):354–362. doi:10.1182/blood-2015-02-628149.
   PubMed Web of Science ®Google Scholar
• Jain T, Litzow MR. 2018. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematol Am Soc Hematol Educ Program. 2018(1):25–34. doi:10.1182/asheducation-2018.1.25.
   PubMedGoogle Scholar
• Jain T, Litzow MR. 2020. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol. 11. doi:10.1177/2040620719899897
   PubMed Web of Science ®Google Scholar
• Jandus C, Boligan KF, Chijioke O. 2014. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 124(4):1810–1820. doi:10.1172/JCI65899.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. 2014b. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Br Med J. 348:g2545. doi:10.1136/bmj.g2545.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones MA, Doshi P. 2014a. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014(4):CD008965. doi:10.1002/14651858.CD008965.pub4.
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E. 2006. Cancer statistics, 2006. CA Cancer J Clin. 56(2):106–130. doi:10.3322/canjclin.56.2.106.
   PubMed Web of Science ®Google Scholar
• Jensenius JC, Jensen PH, McGuire K, Larsen JL, Thiel S. 2003. Recombinant mannan-binding lectin (MBL) for therapy. Biochem Soc Trans. 31(4):763–767. doi:10.1042/bst0310763.
   PubMedGoogle Scholar
• Jiang W, He Y, He W. 2021. Exhausted CD8+ T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 11:622509. doi:10.3389/fimmu.2020.622509.
   PubMed Web of Science ®Google Scholar
• Joo EJ, Wasik BR, Parrish C. 2018. Pre-B acute lymphoblastic leukemia expresses cell surface nucleolin as a 9-O-acetylated sialoglycoprotein. Sci Rep. 8(1):17174. doi:10.1038/s41598-018-33873-2.
   PubMedGoogle Scholar
• Julien S, Bobowski M, Steenackers A, Le Bourhis X, Delannoy P. 2013. How do gangliosides regulate RTKs signaling? Cells. 2(4):751–767. doi:10.3390/cells2040751.
   PubMedGoogle Scholar
• Julien S, Videira PA, Delannoy P. 2012. Sialyl-tn in cancer: (how) did we miss the target? Biomolecules. 2(4):435–466. doi:10.3390/biom2040435.
   PubMedGoogle Scholar
• Jurianz K, Maslak S, Garcia-Schüler H, Fishelson Z, Kirschfink M. 1999. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology. 42(1-3):209–218. doi:10.1016/s0162-3109(99)00006-5.
   PubMedGoogle Scholar
• Juszczynski P, Rodig SJ, Ouyang J. 2010. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res. 16(7):2122–2130. doi:10.1158/1078-0432.CCR-09-2765.
   PubMed Web of Science ®Google Scholar
• Kailemia MJ, Park D, Lebrilla CB. 2017. Glycans and glycoproteins as specific biomarkers for cancer. Anal Bioanal Chem. 409(2):395–410. doi:10.1007/s00216-016-9880-6.
   PubMed Web of Science ®Google Scholar
• Kaji H, Saito H, Yamauchi Y. 2003. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol. 21(6):667–672. doi:10.1038/nbt829.
   PubMed Web of Science ®Google Scholar
• Kandeel EZ, El Sharkawy N, Hanafi M, Samra M, Kamel A. 2020. Tracing leukemia stem cells and their influence on clinical course of adult acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 20(6):383–393. doi:10.1016/j.clml.2019.11.018.
   PubMed Web of Science ®Google Scholar
• Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. 2004. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 95(5):377–384. doi:10.1111/j.1349-7006.2004.tb03219.x.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Stock W, Cassaday RD. 2021. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin Cancer Res. 27(10):2742–2754. doi:10.1158/1078-0432.CCR-20-2399.
   PubMed Web of Science ®Google Scholar
• Kaszuba K, Grzybek M, Orłowski A. 2015. N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Proc Natl Acad Sci USA. 112(14):4334–4339. doi:10.1073/pnas.1503262112.
   PubMed Web of Science ®Google Scholar
• Kawai T, Kato A, Higashi H, Kato S, Naiki M. 1991. Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry. Cancer Res. 51(4):1242–1246.
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. 2020. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 70(2):86–104. doi:10.3322/caac.21596.
   PubMed Web of Science ®Google Scholar
• Keogh D, Thompson R, Larragy R. 2014. Generating novel recombinant prokaryotic lectins with altered carbohydrate binding properties through mutagenesis of the PA-IL protein from Pseudomonas aeruginosa. Biochim Biophys Acta. 1840(6):2091–2104. doi:10.1016/j.bbagen.2014.01.020.
   PubMed Web of Science ®Google Scholar
• Keyel ME, Reynolds CP. 2018. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 13:1–12. doi:10.2147/BTT.S114530.
   PubMedGoogle Scholar
• Khan N, Hills RK, Virgo P. 2017. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia. 31(5):1059–1068. doi:10.1038/leu.2016.309.
   PubMed Web of Science ®Google Scholar
• Khosrowabadi E, Wenta T, Keskitalo S, Manninen A, Kellokumpu S. 2022. Altered glycosylation of several metastasis-associated glycoproteins with terminal GalNAc defines the highly invasive cancer cell phenotype. Oncotarget. 13:73–89. doi:10.18632/oncotarget.28167.
   PubMedGoogle Scholar
• Kieber-Emmons T, Monzavi-Karbassi B, Hutchins LF, Pennisi A, Makhoul I. 2017. Harnessing benefit from targeting tumor associated carbohydrate antigens. Hum Vaccin Immunother. 13(2):323–331. doi:10.1080/21645515.2017.1264789.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Shima T, Takayanagi S. 2010. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 7(6):708–717. doi:10.1016/j.stem.2010.11.014.
   PubMed Web of Science ®Google Scholar
• Kim MY, Yu KR, Kenderian SS. 2018. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 173(6):1439–1453. doi:10.1016/j.cell.2018.05.013.
   PubMed Web of Science ®Google Scholar
• Kim N, Lee DH, Choi WS, Yi E, Kim H, Kim JM, Jin HS, Kim HS. 2021. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. BMB Rep. 54:44–58. doi:10.5483/BMBRep.2021.54.1.214.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Varki A. 1997. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 14(5):569–576. doi:10.1023/a:1018580324971.
   PubMed Web of Science ®Google Scholar
• Kinoshita T. 2020. Biosynthesis and biology of mammalian GPI-anchored proteins. Open Biol. 10(3):190290. doi:10.1098/rsob.190290.
   PubMed Web of Science ®Google Scholar
• Knaus HA, Berglund S, Hackl H. 2018. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 3(21):e120974. doi:10.1172/jci.insight.120974.
   PubMed Web of Science ®Google Scholar
• Kniep B, Monner DA, Burrichter H, Diehl V, Mühlradt PF. 1983. Gangliotriaosylceramide (asialo GM2), a glycosphingolipid marker for cell lines derived from patients with Hodgkin’s disease. J Immunol. 131(3):1591–1594.
   PubMed Web of Science ®Google Scholar
• Koda T, Aosasa M, Asaoka H, Nakaba H, Matsuda H. 2003. Application of tyramide signal amplification for detection of N-glycolylneuraminic acid in human hepatocellular carcinoma. Int J Clin Oncol. 8(5):317–321. doi:10.1007/s10147-003-0346-4.
   PubMedGoogle Scholar
• Kohla G, Stockfleth E, Schauer R. 2002. Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin. Neurochem Res. 27(7-8):583–592. doi:10.1023/a:1020211714104.
   PubMed Web of Science ®Google Scholar
• Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M. 2015. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 8:111. doi:10.1186/s13045-015-0213-6.
   PubMed Web of Science ®Google Scholar
• Końska G, Wójtowicz U, Pituch-Noworolska A. 2008. Mozliwości zastosowania lektyn w diagnostyce i terapii. Cz.I. Zastosowanie diagnostyczne [Possible application of lectins in diagnostics and therapy. Part I. Diagnostic application]. Przegl Lek. 65(4):189–194.
   PubMedGoogle Scholar
• Kooner AS, Yu H, Chen X. 2019. Synthesis of N-glycolylneuraminic acid (Neu5Gc) and its glycosides. Front Immunol. 10:2004. doi:10.3389/fimmu.2019.02004.
   PubMed Web of Science ®Google Scholar
• Koppenol WH, Bounds PL, Dang CV. 2011. Otto Warburg’s contributions to current concepts of cancer metabolism [published correction appears in Nat Rev Cancer. 2011 Aug;11(8):618]. Nat Rev Cancer. 11(5):325–337. doi:10.1038/nrc3038.
   PubMed Web of Science ®Google Scholar
• Kovbasnjuk O, Mourtazina R, Baibakov B. 2005. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci USA. 102(52):19087–19092. doi:10.1073/pnas.0506474102.
   PubMed Web of Science ®Google Scholar
• Kubik S. 2009. Synthetic lectins. Angew Chem Int Ed Engl. 48(10):1722–1725. doi:10.1002/anie.200805497.
   PubMed Web of Science ®Google Scholar
• Kudelka MR, Ju T, Heimburg-Molinaro J, Cummings RD. 2015. Simple sugars to complex disease–mucin-type O-glycans in cancer. Adv Cancer Res. 126:53–135. doi:10.1016/bs.acr.2014.11.002.
   PubMed Web of Science ®Google Scholar
• Kudo D, Rayman P, Horton C. 2003. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res. 63(7):1676–1683.
   PubMed Web of Science ®Google Scholar
• Kudo T, Ikehara Y, Togayachi A. 1998. Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Lab Invest. 78(7):797–811.
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. 2008. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 5(10):588–599. doi:10.1038/ncponc1187.
   PubMedGoogle Scholar
• Kumamoto K, Goto Y, Sekikawa K. 2001. Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Res. 61(11):4620–4627.
   PubMed Web of Science ®Google Scholar
• Kumar V, McNerney ME. 2005. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol. 5(5):363–374. doi:10.1038/nri1603.
   PubMed Web of Science ®Google Scholar
• Kuzmanov U, Kosanam H, Diamandis EP. 2013. The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med. 11:31. doi:10.1186/1741-7015-11-31.
   PubMed Web of Science ®Google Scholar
• Laborda E, Mazagova M, Shao S. 2017. Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 18(11):2259. doi:10.3390/ijms18112259.
   PubMed Web of Science ®Google Scholar
• LaCasse EC, Bray MR, Patterson B. 1999. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood. 94(8):2901–2910.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pötschger U, Valteau-Couanet D. 2018. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 19(12):1617–1629. doi:10.1016/S1470-2045(18)30578-3.
   PubMed Web of Science ®Google Scholar
• Lamble AJ, Tasian SK. 2019. Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Adv. 3(22):3750–3758. doi:10.1182/bloodadvances.2019000357.
   PubMed Web of Science ®Google Scholar
• Lan Y, Hao C, Zeng X. 2016. Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers. Am J Cancer Res. 6(11):2390–2415.
   PubMed Web of Science ®Google Scholar
• Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F. 2020. CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers. 12(2):303. doi:10.3390/cancers12020303.
   PubMed Web of Science ®Google Scholar
• Lau KS, Partridge EA, Grigorian A. 2007. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 129(1):123–134. doi:10.1016/j.cell.2007.01.049.
   PubMed Web of Science ®Google Scholar
• Läubli H, Borsig L. 2019. Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front Immunol. 10:2120. doi:10.3389/fimmu.2019.02120.
   PubMed Web of Science ®Google Scholar
• Lebrilla CB, An HJ. 2009. The prospects of glycan biomarkers for the diagnosis of diseases. Mol Biosyst. 5(1):17–20. doi:10.1039/b811781k.
   PubMedGoogle Scholar
• Lee DH, Choi S, Park Y, Jin HS. 2021. Mucin1 and Mucin16: therapeutic targets for cancer therapy. Pharmaceuticals. 14(10):1053. doi:10.3390/ph14101053.
   Web of Science ®Google Scholar
• Lee J, Ha S, Kim M. 2020. Spatial and temporal diversity of glycome expression in mammalian brain. Proc Natl Acad Sci USA. 117(46):28743–28753. doi:10.1073/pnas.2014207117.
   PubMed Web of Science ®Google Scholar
• Leonard J, Stock W. 2017. Progress in adult ALL: incorporation of new agents to frontline treatment. Hematol Am Soc Hematol Educ Program. 2017(1):28–36. doi:10.1182/asheducation-2017.1.28.
   PubMedGoogle Scholar
• Leonti AR, Pardo L, Alonzo TA, Gerbing RB, Eidenschink Brodersen L, Ries RE, Smith JL, Le Q, Aplenc R, Kolb EA. 2019. Transcriptome profiling of glycosylation genes defines correlation with e-selectin ligand expression and clinical outcome in AML. Blood. 134:3772.
   Web of Science ®Google Scholar
• Levesque JP, Winkler IG, Rasko JE. 2013. Nichotherapy for stem cells: there goes the neighborhood. Bioessays. 35(3):183–190. doi:10.1002/bies.201200111.
   PubMed Web of Science ®Google Scholar
• Leviatan Ben-Arye S, Yu H, Chen X, Padler-Karavani V. 2017. Profiling anti-Neu5Gc IgG in human sera with a sialoglycan microarray assay. J Vis Exp. 125:56094. doi:10.3791/56094.
   Google Scholar
• Levin S, Russell EC, Blanchard D, McWilliams NB, Maurer HM, Mohanakumar T. 1980. Receptors for peanut agglutinin (Arachus hypogea) in childhood acute lymphoblastic leukemia: possible clinical significance. Blood. 55(1):37–39.
   PubMed Web of Science ®Google Scholar
• Ley K. 2003. The role of selectins in inflammation and disease. Trends Mol Med. 9(6):263–268. doi:10.1016/s1471-4914(03)00071-6.
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Chung EM. 2018a. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 33(2):187–201. doi:10.1016/j.ccell.2018.01.009.
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Xia W. 2016. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 7:12632. doi:10.1038/ncomms12632.
   PubMed Web of Science ®Google Scholar
• Li D, Mallory T, Satomura S. 2001. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 313(1-2):15–19. doi:10.1016/s0009-8981(01)00644-1.
   PubMed Web of Science ®Google Scholar
• Li D, Sun H, Bai G. 2018b. α-1,3-Fucosyltransferase-VII siRNA inhibits the expression of SLex and hepatocarcinoma cell proliferation. Int J Mol Med. 42(5):2700–2708. doi:10.3892/ijmm.2018.3850.
   PubMed Web of Science ®Google Scholar
• Liang YJ, Kuo HH, Lin CH. 2010. Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation. Proc Natl Acad Sci USA. 107(52):22564–22569. doi:10.1073/pnas.1007290108.
   PubMed Web of Science ®Google Scholar
• Liberti MV, Locasale JW. 2016. The Warburg effect: how does it benefit cancer cells? [published correction appears in Trends Biochem Sci. 2016 Mar;41(3):287] [published correction appears in Trends Biochem Sci. 2016 Mar;41(3):287]. Trends Biochem Sci. 41(3):211–218. doi:10.1016/j.tibs.2015.12.001.
   PubMed Web of Science ®Google Scholar
• Lichtenstein DA, Schischlik F, Shao L. 2021. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 138(24):2469–2484. doi:10.1182/blood.2021011898.
   PubMed Web of Science ®Google Scholar
• Lih Y-H, Wu C-Y. 2017. Chemical synthesis of sialosides. In: C.S. Bennett, editor. Selective glycosylations: synthetic methods and catalysts. doi:10.1002/9783527696239.ch16
   Google Scholar
• Lim ABM, Curley C, Fong CY. 2018. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. Intern Med J. 48(3):276–285. doi:10.1111/imj.13522.
   PubMed Web of Science ®Google Scholar
• Lim J, Sari-Ak D, Bagga T. 2021. Siglecs as therapeutic targets in cancer. Biology. 10(11):1178. doi:10.3390/biology10111178.
   PubMedGoogle Scholar
• Linenberger ML, Hong T, Flowers D. 2001. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 98(4):988–994. doi:10.1182/blood.v98.4.988.
   PubMed Web of Science ®Google Scholar
• Lingwood CA. 2011. Glycosphingolipid functions [published correction appears in Cold Spring Harb Perspect Biol. 2011 Sep;3(9):a011874]. Cold Spring Harb Perspect Biol. 3(7):a004788. doi:10.1101/cshperspect.a004788.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [published correction appears in immunity 1995 Feb;2(2):following 203]. Immunity. 1(9):793–801. doi:10.1016/s1074-7613(94)80021-9.
   PubMed Web of Science ®Google Scholar
• Liu B, Ma H, Liu Q. 2019b. MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia. J Exp Clin Cancer Res. 38(1):200. doi:10.1186/s13046-019-1179-y.
   PubMedGoogle Scholar
• Liu C, Li Z, Wang S. 2019a. FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma. J Cancer Res Clin Oncol. 145(1):65–76. doi:10.1007/s00432-018-2761-y.
   PubMed Web of Science ®Google Scholar
• Liu YS, Fujita M. 2020. Mammalian GPI-anchor modifications and the enzymes involved. Biochem Soc Trans. 48(3):1129–1138. doi:10.1042/BST20191142.
   PubMed Web of Science ®Google Scholar
• Llop E, Ferrer-Batallé M, Barrabés S. 2016. Improvement of prostate cancer diagnosis by detecting PSA glycosylation-specific changes [published correction appears in theranostics. 2018 Jan 1;8(3):746-748]. Theranostics. 6(8):1190–1204. doi:10.7150/thno.15226.
   PubMed Web of Science ®Google Scholar
• Locasale JW, Cantley LC. 2011. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 14(4):443–451. doi:10.1016/j.cmet.2011.07.014.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zugmaier G, Rizzari C. 2021. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 325(9):843–854. doi:10.1001/jama.2021.0987.
   PubMed Web of Science ®Google Scholar
• Löffler A, Kufer P, Lutterbüse R. 2000. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 95(6):2098–2103.
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF. 2015. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 21(6):581–590. doi:10.1038/nm.3838.
   PubMed Web of Science ®Google Scholar
• Lou YW, Wang PY, Yeh SC. 2014. Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proc Natl Acad Sci USA. 111(7):2482–2487. doi:10.1073/pnas.1400283111.
   PubMed Web of Science ®Google Scholar
• Lu H, Zhou Q, Deshmukh V. 2014. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl. 53(37):9841–9845. doi:10.1002/anie.201405353.
   PubMed Web of Science ®Google Scholar
• Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. 1998. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res. 18(1B):475–480.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhou H, Song X, Shi S, Zhang J, Jia L. 2015. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene. 34(6):726–740. doi:10.1038/onc.2014.7.
   PubMed Web of Science ®Google Scholar
• Ma Z, Vosseller K. 2014. Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem. 289(50):34457–34465. doi:10.1074/jbc.R114.577718.
   PubMed Web of Science ®Google Scholar
• Maak M, Nitsche U, Keller L. 2011. Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. Mol Cancer Ther. 10(10):1918–1928. doi:10.1158/1535-7163.MCT-11-0006.
   PubMed Web of Science ®Google Scholar
• Macauley MS, Crocker PR, Paulson JC. 2014. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 14(10):653–666. doi:10.1038/nri3737.
   PubMed Web of Science ®Google Scholar
• Magalhães A, Duarte HO, Reis CA. 2017. Aberrant glycosylation in cancer: a novel molecular mechanism controlling metastasis. Cancer Cell. 31(6):733–735. doi:10.1016/j.ccell.2017.05.012.
   PubMed Web of Science ®Google Scholar
• Mahalingam A, Geonnotti AR, Balzarini J, Kiser PF. 2011. Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm. 8(6):2465–2475. doi:10.1021/mp2002957.
   PubMedGoogle Scholar
• Makhoul I, Hutchins L, Emanuel PD. 2015. Moving a carbohydrate mimetic peptide into the clinic. Hum Vaccine Immunother. 11(1):37–44. doi:10.4161/hv.34300.
   PubMed Web of Science ®Google Scholar
• Mamidi S, Höne S, Teufel C, Sellner L, Zenz T, Kirschfink M. 2015. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology. 4(3):e979688. doi:10.4161/2162402X.2014.979688.
   PubMed Web of Science ®Google Scholar
• Mandal C, Schwartz-Albiez R, Vlasak R. 2015. Functions and biosynthesis of O-acetylated sialic acids. Top Curr Chem. 366:1–30. doi:10.1007/128_2011_310.
   PubMed Web of Science ®Google Scholar
• Mandal C, Srinivasan GV, Chowdhury S. 2009. High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status. Glycoconj J. 26(1):57–73. doi:10.1007/s10719-008-9163-3.
   PubMed Web of Science ®Google Scholar
• Mangeney M, Lingwood CA, Taga S, Caillou B, Tursz T, Wiels J. 1993. Apoptosis induced in Burkitt’s lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 53(21):5314–5319.
   PubMed Web of Science ®Google Scholar
• Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J. 1991. CD77: an antigen of germinal center B cells entering apoptosis. Eur J Immunol. 21(5):1131–1140. doi:10.1002/eji.1830210507.
   PubMed Web of Science ®Google Scholar
• Mardiana S, Gill S. 2020. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 10:697. doi:10.3389/fonc.2020.00697.
   PubMed Web of Science ®Google Scholar
• Mardiros A, Forman SJ, Budde LE. 2015. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol. 22(6):484–488. doi:10.1097/MOH.0000000000000190.
   PubMed Web of Science ®Google Scholar
• Marques ETA Jr. 2000. Fucosyltransferases. In: Carbohydrate in chemistry and biology. Weinheim: Wiley-VCH; p. 197–211. doi:10.1002/9783527618255.ch50.
   Google Scholar
• Marquina G, Waki H, Fernandez LE. 1996. Gangliosides expressed in human breast cancer. Cancer Res. 56(22):5165–5171.
   PubMed Web of Science ®Google Scholar
• Marshall AS, Willment JA, Pyz E. 2006. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur J Immunol. 36(8):2159–2169. doi:10.1002/eji.200535628.
   PubMed Web of Science ®Google Scholar
• Martinez-Palomo A, Braislovsky C, Bernhard W. 1969. Ultrastructural modifications of the cell surface and intercellular contacts of some transformed cell strains. Cancer Res. 29(4):925–937.
   PubMed Web of Science ®Google Scholar
• Masih KE, Ligon JA, Yates B. 2021. Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia. Pediatr Blood Cancer. 68(10):e29247. doi:10.1002/pbc.29247.
   PubMed Web of Science ®Google Scholar
• Mason CP, Tarr AW. 2015. Human lectins and their roles in viral infections. Molecules. 20(2):2229–2271. doi:10.3390/molecules20022229.
   PubMed Web of Science ®Google Scholar
• Matoba Y, Sato Y, Oda K, Hatori Y, Morimoto K. 2021. Lectins engineered to favor a glycan-binding conformation have enhanced antiviral activity. J Biol Chem. 296:100698. doi:10.1016/j.jbc.2021.100698.
   PubMed Web of Science ®Google Scholar
• Matsuura N, Narita T, Hiraiwa N. 1998. Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer. Int J Oncol. 12(5):1157–1164. doi:10.3892/ijo.12.5.1157.
   PubMed Web of Science ®Google Scholar
• Maude SL. 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448.
   PubMed Web of Science ®Google Scholar
• Mazalovska M, Kouokam JC. 2018. Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections. Biomed Res Int. 2018:3750646. doi:10.1155/2018/3750646.
   PubMed Web of Science ®Google Scholar
• McEver RP, Cummings RD. 1997. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 100(Suppl. 11):S97–S103.
   PubMed Web of Science ®Google Scholar
• Meads MB, Hazlehurst LA, Dalton WS. 2008. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 14(9):2519–2526. doi:10.1158/1078-0432.CCR-07-2223.
   PubMed Web of Science ®Google Scholar
• Meany DL, Chan DW. 2011. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteom. 8(1):7. doi:10.1186/1559-0275-8-7.
   PubMedGoogle Scholar
• Mereiter S, Balmaña M, Campos D, Gomes J, Reis CA. 2019. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell. 36(1):6–16. doi:10.1016/j.ccell.2019.06.006.
   PubMed Web of Science ®Google Scholar
• Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. 2013. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 8(4):e60348. doi:10.1371/journal.pone.0060348.
   PubMed Web of Science ®Google Scholar
• Misaghian N, Ligresti G, Steelman LS. 2009. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 23(1):25–42. doi:10.1038/leu.2008.246.
   PubMed Web of Science ®Google Scholar
• Mishra A, Behura A, Mawatwal S. 2019. Structure-function and application of plant lectins in disease biology and immunity. Food Chem Toxicol. 134:110827. doi:10.1016/j.fct.2019.110827.
   PubMed Web of Science ®Google Scholar
• Mitchell CA, Ramessar K, O’Keefe BR. 2017. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res. 142:37–54. doi:10.1016/j.antiviral.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Miyagi T. 2008. Aberrant expression of sialidase and cancer progression. Proc Jpn Acad Ser B Phys Biol Sci. 84(10):407–418. doi:10.2183/pjab.84.407.
   PubMed Web of Science ®Google Scholar
• Miyagi T, Yamaguchi K. 2007. Comprehensive glycoscience. In: Kamerling J. P., Boons G., Lee Y. C., Suzuki A., Taniguchi N., Voragen A. G. J., editor. Biochemistry of glycans: sialic acids. Amsterdam: Elsevier; p. 297–322.
   Google Scholar
• Miyazaki K, Sakuma K, Kawamura YI. 2012. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9. J Immunol. 188(9):4690–4700. doi:10.4049/jimmunol.1100605.
   PubMed Web of Science ®Google Scholar
• Miyoshi E, Terao M, Kamada Y. 2012. Physiological roles of N-acetylglucosaminyltransferase V(GnT-V) in mice. BMB Rep. 45(10):554–559. doi:10.5483/bmbrep.2012.45.10.190.
   PubMed Web of Science ®Google Scholar
• Mnich ME, van Dalen R, van Sorge NM. 2020. C-type lectin receptors in host defense against bacterial pathogens. Front Cell Infect Microbiol. 10:309. doi:10.3389/fcimb.2020.00309.
   PubMed Web of Science ®Google Scholar
• Modenutti CP, Capurro JIB, Di Lella S, Martí MA. 2019. The structural biology of galectin-ligand recognition: current advances in modeling tools, protein engineering, and inhibitor design. Front Chem. 7:823. doi:10.3389/fchem.2019.00823.
   PubMed Web of Science ®Google Scholar
• Mohseni M, Uludag H, Brandwein JM. 2018. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. Am J Blood Res. 8(4):29–56.
   PubMed Web of Science ®Google Scholar
• Mondal N, Buffone A, Stolfa G. 2015. ST3Gal-4 is the primary sialyltransferase regulating the synthesis of E-, P-, and L-selectin ligands on human myeloid leukocytes. Blood. 125(4):687–696. doi:10.1182/blood-2014-07-588590.
   PubMed Web of Science ®Google Scholar
• Mondal S, Chandra S, Mandal C. 2010. Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia. Leuk Res. 34(4):463–470. doi:10.1016/j.leukres.2009.07.042.
   PubMed Web of Science ®Google Scholar
• Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. 2013. Tumor-associated glycans and immune surveillance. Vaccines. 1(2):174–203. doi:10.3390/vaccines1020174.
   Google Scholar
• Moremen KW, Tiemeyer M, Nairn AV. 2012. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 13(7):448–462. doi:10.1038/nrm3383.
   PubMed Web of Science ®Google Scholar
• Morita K, Wang F, Jahn K. 2020. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics [published correction appears in Nat Commun. 2020 Nov 19;11(1):5996] [published correction appears in Nat Commun. 2021 May 10;12(1):2823]. Nat Commun. 11(1):5327. doi:10.1038/s41467-020-19119-8.
   PubMed Web of Science ®Google Scholar
• Morton DL, Barth A. 1996. Vaccine therapy for malignant melanoma. CA Cancer J Clin. 46(4):225–244. doi:10.3322/canjclin.46.4.225.
   PubMed Web of Science ®Google Scholar
• Moscona A. 2005. Neuraminidase inhibitors for influenza. N Engl J Med. 353(13):1363–1373. doi:10.1056/NEJMra050740.
   PubMed Web of Science ®Google Scholar
• Moyer VA. 2012. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 157(2):120–134. doi:10.7326/0003-4819-157-2-201207170-00459.
   PubMed Web of Science ®Google Scholar
• Moynihan KD, Irvine DJ. 2017. Roles for innate immunity in combination immunotherapies. Cancer Res. 77(19):5215–5221. doi:10.1158/0008-5472.CAN-17-1340.
   PubMed Web of Science ®Google Scholar
• Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. 1987. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 47(4):1098–1104.
   PubMed Web of Science ®Google Scholar
• Mukherjee K, Chava AK, Mandal C. 2008. O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia. J Cell Biochem. 105(3):724–734. doi:10.1002/jcb.21867.
   PubMed Web of Science ®Google Scholar
• Munkley J, Elliott DJ. 2016. Hallmarks of glycosylation in cancer. Oncotarget. 7(23):35478–35489. doi:10.18632/oncotarget.8155.
   PubMed Web of Science ®Google Scholar
• Myers D, Wrobleski S, Londy F. 2002. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb Haemost. 87(3):374–382.
   PubMed Web of Science ®Google Scholar
• Myers DD, Schaub R, Wrobleski SK. 2001. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost. 85(3):423–429.
   PubMed Web of Science ®Google Scholar
• Nakagoe T, Fukushima K, Tanaka K. 2002. Evaluation of sialyl Lewis(a), sialyl Lewis(x), and sialyl Tn antigens expression levels as predictors of recurrence after curative surgery in node-negative colorectal cancer patients. J Exp Clin Cancer Res. 21(1):107–113.
   PubMed Web of Science ®Google Scholar
• Nakagoe T, Sawai T, Tsuji T. 2001. Circulating sialyl Lewis(x), sialyl Lewis(a), and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels. J Gastroenterol. 36(3):166–172. doi:10.1007/s005350170124.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogino H, Nojiri H, Kitagawa S, Saito M. 1989. Characteristic incorporation of ganglioside GM3, which induces monocytic differentiation in human myelogenous leukemia HL-60 cells. Biochem Biophys Res Commun. 161(2):782–789. doi:10.1016/0006-291x(89)92668-5.
   PubMed Web of Science ®Google Scholar
• Nascimento KS, Cunha AI, Nascimento KS, Cavada BS, Azevedo AM, Aires-Barros MR. 2012. An overview of lectins purification strategies. J Mol Recognit. 25(11):527–541. doi:10.1002/jmr.2200.
   PubMed Web of Science ®Google Scholar
• Neth O, Hann I, Turner MW, Klein NJ. 2001. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet. 358(9282):614–618. doi:10.1016/S0140-6736(01)05776-2.
   PubMed Web of Science ®Google Scholar
• Neth OW, Bajaj-Elliott M, Turner MW, Klein NJ. 2005. Susceptibility to infection in patients with neutropenia: the role of the innate immune system. Br J Haematol. 129(6):713–722. doi:10.1111/j.1365-2141.2005.05462.x.
   PubMed Web of Science ®Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ. 2016. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 374(26):2542–2552. doi:10.1056/NEJMoa1603702.
   PubMed Web of Science ®Google Scholar
• Niemann CU, Kjeldsen L, Ralfkiaer E, Jensen MK, Borregaard N. 2007. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia. 21(12):2406–2410. doi:10.1038/sj.leu.2404975.
   PubMed Web of Science ®Google Scholar
• Notova S, Bonnardel F, Rosato F. 2022. A pore-forming β-trefoil lectin with specificity for the tumor-related glycosphingolipid Gb3. bioRxiv. doi:10.1101/2022.02.10.479907.
   Google Scholar
• Oberley MJ, Gaynon PS, Bhojwani D. 2018. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer. 65(9):e27265. doi:10.1002/pbc.27265.
   PubMed Web of Science ®Google Scholar
• O’Brien RM, Cannon A, Reynolds JV, Lysaght J, Lynam-Lennon N. 2021. Complement in tumourigenesis and the response to cancer therapy. Cancers. 13(6):1209. doi:10.3390/cancers13061209.
   PubMed Web of Science ®Google Scholar
• Oiseth SJ, Aziz MSA-E. 2017. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 3:250–261.
   Google Scholar
• Ok CY, Young KH. 2017. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 10(1):103. doi:10.1186/s13045-017-0474-3.
   PubMed Web of Science ®Google Scholar
• Okada M, Furukawa K, Yamashiro S. 1996. High expression of ganglioside alpha-2,8-sialyltransferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I. Cancer Res. 56(12):2844–2848.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Teixeira JA, Domingues L. 2013. Recombinant lectins: an array of tailor-made glycan-interaction biosynthetic tools. Crit Rev Biotechnol. 33(1):66–80. doi:10.3109/07388551.2012.670614.
   PubMed Web of Science ®Google Scholar
• Oliveira T, Zhang M, Joo EJ. 2021. Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia. Theranostics. 11(19):9519–9537. doi:10.7150/thno.65398.
   PubMed Web of Science ®Google Scholar
• Ono M, Hakomori S. 2004. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J. 20(1):71–78. doi:10.1023/B:GLYC.0000018019.22070.7d.
   PubMed Web of Science ®Google Scholar
• Opdenakker G, Rudd PM, Ponting CP, Dwek RA. 1993. Concepts and principles of glycobiology. FASEB J. 7(14):1330–1337. doi:10.1096/fasebj.7.14.8224606.
   PubMed Web of Science ®Google Scholar
• Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW. 2001. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function–implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol. 126(3):403–411. doi:10.1046/j.1365-2249.2001.01692.x.
   PubMed Web of Science ®Google Scholar
• Pal S, Ghosh S, Mandal C. 2004. Purification and characterization of 9-O-acetylated sialoglycoproteins from leukemic cells and their potential as immunological tool for monitoring childhood acute lymphoblastic leukemia. Glycobiology. 14(10):859–870. doi:10.1093/glycob/cwh111.
   PubMed Web of Science ®Google Scholar
• Pang X, Li H, Guan F, Li X. 2018. Multiple roles of glycans in hematological malignancies. Front Oncol. 8:364. doi:10.3389/fonc.2018.00364.
   PubMed Web of Science ®Google Scholar
• Parameswaran R, Lim M, Arutyunyan A. 2013. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia. J Exp Med. 210(4):805–819. doi:10.1084/jem.20121482.
   PubMed Web of Science ®Google Scholar
• Park DD, Chen J, Kudelka MR. 2021. Resident and elicited murine macrophages differ in expression of their glycomes and glycan-binding proteins. Cell Chem Biol. 28(4):567–582. doi:10.1016/j.chembiol.2020.12.005.
   PubMed Web of Science ®Google Scholar
• Park JJ, Lee M. 2013. Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut Liver. 7(6):629–641. doi:10.5009/gnl.2013.7.6.629.
   PubMed Web of Science ®Google Scholar
• Paszek MJ, DuFort CC, Rossier O. 2014. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 511(7509):319–325. doi:10.1038/nature13535.
   PubMed Web of Science ®Google Scholar
• Patankar MS, Jing Y, Morrison JC. 2005. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol. 99(3):704–713. doi:10.1016/j.ygyno.2005.07.030.
   PubMed Web of Science ®Google Scholar
• Patil S, Rao RS, Majumdar B. 2015. T-cell exhaustion and cancer immunotherapy. J Int Oral Health. 7(8):i–ii.
   Google Scholar
• Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. 2019. Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 17(3):166–175.
   PubMed Web of Science ®Google Scholar
• Paz H, Joo EJ, Chou CH. 2018. Treatment of B-cell precursor acute lymphoblastic leukemia with the galectin-1 inhibitor PTX008. J Exp Clin Cancer Res. 37(1):67. doi:10.1186/s13046-018-0721-7.
   PubMedGoogle Scholar
• Pearce OM, Varki A. 2010. Chemo-enzymatic synthesis of the carbohydrate antigen N-glycolylneuraminic acid from glucose. Carbohydr Res. 345(9):1225–1229. doi:10.1016/j.carres.2010.04.003.
   PubMed Web of Science ®Google Scholar
• Peixoto A, Relvas-Santos M, Azevedo R, Santos LL, Ferreira JA. 2019. Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks. Front Oncol. 9:380. doi:10.3389/fonc.2019.00380.
   PubMed Web of Science ®Google Scholar
• Pena C, Mirandola L, Figueroa JA. 2014. Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness. Ann Transl Med. 2(9):87. doi:10.3978/j.issn.2305-5839.2014.09.14.
   PubMedGoogle Scholar
• Peterson K, Kumar R, Stenström O. 2018. Systematic tuning of fluoro-galectin-3 interactions provides thiodigalactoside derivatives with single-digit nM affinity and high selectivity. J Med Chem. 61(3):1164–1175. doi:10.1021/acs.jmedchem.7b01626.
   PubMed Web of Science ®Google Scholar
• Petretti T, Schulze B, Schlag PM, Kemmner W. 1999. Altered mRNA expression of glycosyltransferases in human gastric carcinomas. Biochim Biophys Acta. 1428(2-3):209–218. doi:10.1016/s0304-4165(99)00080-x.
   PubMed Web of Science ®Google Scholar
• Petrov JC, Wada M, Pinz KG. 2018. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia. 32(6):1317–1326. doi:10.1038/s41375-018-0075-3.
   PubMed Web of Science ®Google Scholar
• Pieters R, Kaspers GJ, van Wering ER. 1993. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia. 7(3):392–397.
   PubMed Web of Science ®Google Scholar
• Pihikova D, Kasak P, Kubanikova P, Sokol R, Tkac J. 2016. Aberrant sialylation of a prostate-specific antigen: electrochemical label-free glycoprofiling in prostate cancer serum samples. Anal Chim Acta. 934:72–79. doi:10.1016/j.aca.2016.06.043.
   PubMed Web of Science ®Google Scholar
• Pillai V, Muralidharan K, Meng W. 2019. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 3(22):3539–3549. doi:10.1182/bloodadvances.2019000692.
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. 2015. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 15(9):540–555. doi:10.1038/nrc3982.
   PubMed Web of Science ®Google Scholar
• Ploessl C, Pan A, Maples KT, Lowe DK. 2016. Dinutuximab: an anti-GD2 monoclonal antibody for high-risk neuroblastoma. Ann Pharmacother. 50(5):416–422. doi:10.1177/1060028016632013.
   PubMed Web of Science ®Google Scholar
• Poggi A, Zocchi MR. 2021. Natural killer cells and immune-checkpoint inhibitor therapy: current knowledge and new challenges. Mol Ther Oncolyt. 24:26–42. doi:10.1016/j.omto.2021.11.016.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Loken M. 2012. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 119(16):3705–3711. doi:10.1182/blood-2011-12-398370.
   PubMed Web of Science ®Google Scholar
• Ponath P, Menezes D, Pan C. 2018. A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer. Clin Cancer Res. 24(20):5178–5189. doi:10.1158/1078-0432.CCR-18-0018.
   PubMed Web of Science ®Google Scholar
• Portell CA, Wenzell CM, Advani AS. 2013. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 5(Suppl. 1):5–11. doi:10.2147/CPAA.S42689.
   PubMedGoogle Scholar
• Posey AD, Schwab RD, Boesteanu AC. 2016. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 44(6):1444–1454. doi:10.1016/j.immuni.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Prendergast GC. 2008. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 27(28):3889–3900. doi:10.1038/onc.2008.35.
   PubMed Web of Science ®Google Scholar
• Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. 1982. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med. 155(4):1133–1147. doi:10.1084/jem.155.4.1133.
   PubMed Web of Science ®Google Scholar
• Purushothaman A, Toole BP. 2014. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization. J Biol Chem. 289(9):5499–5509. doi:10.1074/jbc.M113.532143.
   PubMed Web of Science ®Google Scholar
• Qin H, Ishii K, Nguyen S. 2018. Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor. Blood. 132(18):1899–1910. doi:10.1182/blood-2017-12-815548.
   PubMed Web of Science ®Google Scholar
• Qin W, Hu L, Zhang X. 2019. The diverse function of PD-1/PD-L pathway beyond cancer. Front Immunol. 10:2298. doi:10.3389/fimmu.2019.02298.
   PubMed Web of Science ®Google Scholar
• Rack B, Jückstock J, Trapp E. 2016. CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. Tumour Biol. 37(10):13769–13775. doi:10.1007/s13277-016-5171-2.
   PubMedGoogle Scholar
• Raetz EA, Teachey DT. 2016. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016(1):580–588. doi:10.1182/asheducation-2016.1.580.
   PubMed Web of Science ®Google Scholar
• Ragoonanan D, Khazal SJ, Abdel-Azim H. 2021. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer [published correction appears in Nat Rev Clin Oncol. 2021 Mar 17]. Nat Rev Clin Oncol. 18(7):435–453. doi:10.1038/s41571-021-00474-4.
   PubMed Web of Science ®Google Scholar
• Rani CS, Abe A, Chang Y. 1995. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J Biol Chem. 270(6):2859–2867. doi:10.1074/jbc.270.6.2859.
   PubMed Web of Science ®Google Scholar
• Rasche L, Vago L, Mutis T. 2022. Tumour escape from CAR-T cells. In: Kröger N., Gribben J., Chabannon C., Yakoub-Agha I., Einsele H, editor. The EBMT/EHA CAR-T cell handbook. Cham: Springer. doi:10.1007/978-3-030-94353-0_4
   Google Scholar
• Rashidbaghan A, Mostafaie A, Yazdani Y, Mansouri K. 2020. Urtica dioica agglutinin (a plant lectin) has a caspase-dependent apoptosis induction effect on the acute lymphoblastic leukemia cell line. Cell Mol Biol. 66(6):121–126.
   PubMed Web of Science ®Google Scholar
• Rassidakis GZ, Goy A, Medeiros LJ. 2003. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res. 9(6):2213–2220.
   PubMed Web of Science ®Google Scholar
• Ravindranaths MH, Paulson JC, Irie RF. 1988. Human melanoma antigen O-acetylated ganglioside GD3 is recognized by cancer antennarius lectin. J Biol Chem. 263(4):2079–2086.
   PubMed Web of Science ®Google Scholar
• Ravn V, Dabelsteen E. 2000. Tissue distribution of histo-blood group antigens. APMIS. 108(1):1–28. doi:10.1034/j.1600-0463.2000.d01-1.x.
   PubMed Web of Science ®Google Scholar
• Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. 1998. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 58(18):4066–4070.
   PubMed Web of Science ®Google Scholar
• Reily C, Stewart TJ, Renfrow MB, Novak J. 2019. Glycosylation in health and disease. Nat Rev Nephrol. 15(6):346–366. doi:10.1038/s41581-019-0129-4.
   PubMed Web of Science ®Google Scholar
• Reismüller B, Attarbaschi A, Peters C. 2009. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria – a population-based report of the Austrian Berlin-Frankfurt-münster (BFM) study group. Br J Haematol. 144(4):559–570. doi:10.1111/j.1365-2141.2008.07499.x.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Biniaminov M, Rosenthal E, Sharon N, Ramot B. 1979. Interaction of peanut agglutinin with normal human lymphocytes and with leukemic cells. Proc Natl Acad Sci USA. 76(1):447–451. doi:10.1073/pnas.76.1.447.
   PubMed Web of Science ®Google Scholar
• Rettig M, Godwin J, Vey N. 2017. Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: rationale for combining flotetuzumab and anti-PD-1/PD-L1 immunotherapies [abstract]. Blood. 130(Suppl. 1).
   Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature. 414(6859):105–111. doi:10.1038/35102167.
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Maloney DG. 2011. Rituximab resistance. Best Pract Res Clin Haematol. 24(2):203–216. doi:10.1016/j.beha.2011.02.009.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Corbacioglu S. 2020. Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J. 10(3):29. doi:10.1038/s41408-020-0286-5.
   PubMed Web of Science ®Google Scholar
• Richter M, Yumul R, Saydaminova K. 2016. Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic. Mol Ther Methods Clin Dev. 5:16013. doi:10.1038/mtm.2016.13.
   PubMedGoogle Scholar
• Riley JL, Mao M, Kobayashi S. 2002. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci USA. 99(18):11790–11795. doi:10.1073/pnas.162359999.
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Neeson PJ, Khot A. 2013. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 21(11):2122–2129. doi:10.1038/mt.2013.154.
   PubMed Web of Science ®Google Scholar
• RodrÍguez E, Schetters STT, van Kooyk Y. 2018. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 18(3):204–211. doi:10.1038/nri.2018.3.
   PubMed Web of Science ®Google Scholar
• Rodrigues Mantuano N, Natoli M, Zippelius A, Läubli H. 2020. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. J Immunother Cancer. 8(2):e001222. doi:10.1136/jitc-2020-001222.
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Boelaars K, Brown K. 2021. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat Commun. 12(1):1270. doi:10.1038/s41467-021-21550-4.
   PubMed Web of Science ®Google Scholar
• Rosen SD, Bertozzi CR. 1994. The selectins and their ligands. Curr Opin Cell Biol. 6(5):663–673. doi:10.1016/0955-0674(94)90092-2.
   PubMed Web of Science ®Google Scholar
• Rosenstock P, Kaufmann T. 2021. Sialic acids and their influence on human NK cell function. Cells. 10:263. doi:10.3390/cells10020263.
   PubMed Web of Science ®Google Scholar
• Rossi V, Cseh S, Bally I, Thielens NM, Jensenius JC, Arlaud GJ. 2001. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2. J Biol Chem. 276(44):40880–40887. doi:10.1074/jbc.M105934200.
   PubMed Web of Science ®Google Scholar
• Roth J, Zuber C, Wagner P. 1988. Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms tumor. Proc Natl Acad Sci USA. 85(9):2999–3003. doi:10.1073/pnas.85.9.2999.
   PubMed Web of Science ®Google Scholar
• Roth P, Winklhofer S, Müller AMS. 2021. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 97:102189. doi:10.1016/j.ctrv.2021.102189.
   PubMed Web of Science ®Google Scholar
• Rubinstein N, Alvarez M, Zwirner NW. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 5(3):241–251. doi:10.1016/s1535-6108(04)00024-8.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Kaspers GJ. 2021. How I treat pediatric acute myeloid leukemia. Blood. 138(12):1009–1018. doi:10.1182/blood.2021011694.
   PubMed Web of Science ®Google Scholar
• Ruhaak LR, Xu G, Li Q, Goonatilleke E, Lebrilla CB. 2018. Mass spectrometry approaches to glycomic and glycoproteomic analyses. Chem Rev. 118(17):7886–7930. doi:10.1021/acs.chemrev.7b00732.
   PubMed Web of Science ®Google Scholar
• Rupp LJ, Schumann K, Roybal KT. 2017. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 7(1):737. doi:10.1038/s41598-017-00462-8.
   PubMed Web of Science ®Google Scholar
• Saad AAD. 2021. Recombinant lectins as pioneering anti-viral agents against COVID-19. Hematol Transfus Int J. 9(4):77–79. doi:10.15406/htij.2021.09.00259.
   Google Scholar
• Sakuma K, Aoki M, Kannagi R. 2012. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci USA. 109(20):7776–7781. doi:10.1073/pnas.1111135109.
   PubMed Web of Science ®Google Scholar
• Samraj AN, Bertrand KA, Luben R. 2018. Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: total antibody levels are associated with colorectal cancer risk. PLoS One. 13(6):e0197464. doi:10.1371/journal.pone.0197464.
   PubMed Web of Science ®Google Scholar
• Samraj AN, Läubli H, Varki N, Varki A. 2014. Involvement of a non-human sialic acid in human cancer. Front Oncol. 4:33. doi:10.3389/fonc.2014.00033.
   PubMedGoogle Scholar
• Sander VA, Corigliano MG, Clemente M. 2019. Promising plant-derived adjuvants in the development of coccidial vaccines. Front Vet Sci. 6:20. doi:10.3389/fvets.2019.00020.
   PubMed Web of Science ®Google Scholar
• Sanford BH. 1967. An alteration in tumor histocompatibility induced by neuraminidase. Transplantation. 5(5):1273–1279. doi:10.1097/00007890-196709000-00005.
   PubMedGoogle Scholar
• Santamaria S, Delgado M, Kremer L, Garcia-Sanz JA. 2017. Will a mAb-based immunotherapy directed against cancer stem cells Be feasible? Front Immunol. 8:1509. doi:10.3389/fimmu.2017.01509.
   PubMed Web of Science ®Google Scholar
• Sarnataro D, Pepe A, Zurzolo C. 2017. Cell biology of prion protein. Prog Mol Biol Transl Sci. 150:57–82. doi:10.1016/bs.pmbts.2017.06.018.
   PubMed Web of Science ®Google Scholar
• Schauer R. 2000. Achievements and challenges of sialic acid research. Glycoconj J. 17(7–9):485–499. doi:10.1023/a:1011062223612.
   PubMed Web of Science ®Google Scholar
• Schauer R, Srinivasan GV, Wipfler D, Kniep B, Schwartz-Albiez R. 2011. O-acetylated sialic acids and their role in immune defense. Adv Exp Med Biol. 705:525–548. doi:10.1007/978-1-4419-7877-6_28.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A. 2012. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 119(6):1599–1606. doi:10.1182/blood-2011-08-375840.
   PubMed Web of Science ®Google Scholar
• Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R. 1998. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother. 46(4):201–212. doi:10.1007/s002620050479.
   PubMed Web of Science ®Google Scholar
• Schwartz-Albiez R, Dörken B, Möller P, Brodin NT, Monner DA, Kniep B. 1990. Neutral glycosphingolipids of the globo-series characterize activation stages corresponding to germinal center B cells. Int Immunol. 2(10):929–936. doi:10.1093/intimm/2.10.929.
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Hopkins W. 2001. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol. 19(19):3976–3987. doi:10.1200/JCO.2001.19.19.3976.
   PubMed Web of Science ®Google Scholar
• Sewell R, Bäckström M, Dalziel M. 2006. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 281(6):3586–3594. doi:10.1074/jbc.M511826200.
   PubMed Web of Science ®Google Scholar
• Shah NN, Fry TJ. 2019. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 16(6):372–385. doi:10.1038/s41571-019-0184-6.
   PubMed Web of Science ®Google Scholar
• Shah NN, Maatman T, Hari P, Johnson B. 2019. Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol. 9:146. doi:10.3389/fonc.2019.00146.
   PubMed Web of Science ®Google Scholar
• Shah NN, O’Brien MM, Yuan C, Ji L, Xu X, Rheingold SR. 2020. Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL). J Clin Oncol. 38(Suppl. 15):10519.
   Web of Science ®Google Scholar
• Shan M, Yang D, Dou H, Zhang L. 2019. Fucosylation in cancer biology and its clinical applications. Prog Mol Biol Transl Sci. 162:93–119. doi:10.1016/bs.pmbts.2019.01.002.
   PubMed Web of Science ®Google Scholar
• Shang Y, Zhou F. 2019. Current advances in immunotherapy for acute leukemia: an overview of antibody, chimeric antigen receptor, immune checkpoint, and natural killer. Front Oncol. 9:917. doi:10.3389/fonc.2019.00917.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. 2017. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168(4):707–723. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Sharma V, Vijayan M, Surolia A. 1996. Imparting exquisite specificity to peanut agglutinin for the tumor-associated Thomsen-Friedenreich antigen by redesign of its combining site. J Biol Chem. 271(35):21209–21213. doi:10.1074/jbc.271.35.21209.
   PubMed Web of Science ®Google Scholar
• Shewell LK, Day CJ, Kutasovic JR, Abrahams JL, Wang J, Poole J, Niland C, Ferguson K, Saunus JM, Lakhani SR, et al. 2021. N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease. bioRxiv: n. pag.
   Google Scholar
• Shintani Y, Takashima S, Asano Y. 2006. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J. 25(13):3045–3055. doi:10.1038/sj.emboj.7601188.
   PubMed Web of Science ®Google Scholar
• Short NJ, Konopleva M, Kadia TM. 2020. Advances in the Treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 10(4):506–525. doi:10.1158/2159-8290.CD-19-1011.
   PubMed Web of Science ®Google Scholar
• Shukla N, Sulis ML. 2021. Blinatumomab for treatment of children with high-risk relapsed B-cell acute lymphoblastic leukemia. JAMA. 325(9):830–832. doi:10.1001/jama.2021.1395.
   PubMed Web of Science ®Google Scholar
• Silsirivanit A. 2019. Chapter five – glycosylation markers in cancer. In: Gregory S. Makowski, editor. Advances in clinical chemistry. Elsevier; p. 189–213. doi:10.1016/bs.acc.2018.12.005
   Google Scholar
• Singh JP, Zhang K, Wu J, Yang X. 2015. O-GlcNAc signaling in cancer metabolism and epigenetics. Cancer Lett. 356(2 Pt A):244–250. doi:10.1016/j.canlet.2014.04.014.
   PubMed Web of Science ®Google Scholar
• Singrang N, Laophetsakunchai S, Tran BN, Matsudaira PT, Tassanakajon A, Wangkanont K. 2021. Biochemical and structural characterization of a recombinant fibrinogen-related lectin from Penaeus monodon. Sci Rep. 11(1):2934. doi:10.1038/s41598-021-82301-5.
   PubMed Web of Science ®Google Scholar
• Sinha D, Bhattacharya DK, Mandal C. 1999a. A colorimetric assay to evaluate the chemotherapeutic response of children with acute lymphoblastic leukemia (ALL) employing achatininH: a 9-O-acetyl sialic acid binding lectin. Leuk Res. 23(9):803–809. doi:10.1016/s0145-2126(99)00093-4.
   PubMed Web of Science ®Google Scholar
• Sinha D, Mandal C, Bhattacharya DK. 1999b. Development of a simple, blood based lymphoproliferation assay to assess the clinical status of patients with acute lymphoblastic leukemia. Leuk Res. 23(5):433–439. doi:10.1016/s0145-2126(98)00184-2.
   PubMed Web of Science ®Google Scholar
• Siukstaite L, Imberty A, Römer W. 2021. Structural diversities of lectins binding to the glycosphingolipid Gb3. Front Mol Biosci. 8:704685. doi:10.3389/fmolb.2021.704685.
   PubMed Web of Science ®Google Scholar
• Skliris A, Labropoulou VT, Papachristou DJ, Aletras A, Karamanos NK, Theocharis AD. 2013. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J. 280(10):2342–2352. doi:10.1111/febs.12179.
   PubMed Web of Science ®Google Scholar
• Slesak B, Bogusławska-Jaworska J, Pejcz J, Harłozińska A. 1989. Binding of lectins to human leukaemic cells. Folia Haematol Int Mag Klin Morphol Blutforsch. 116(2):251–259.
   PubMedGoogle Scholar
• Slesak B, Harłozińska-Szmyrka A, Frydecka I. 1990. Lectin binding ability of B-chronic lymphocytic leukaemia cells. Folia Haematol Int Mag Klin Morphol Blutforsch. 117(1):31–35.
   PubMedGoogle Scholar
• Smith BAH, Bertozzi CR. 2021. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans [published correction appears in Nat Rev Drug Discov. 2021 Feb 8;:]. Nat Rev Drug Discov. 20(3):217–243. doi:10.1038/s41573-020-00093-1.
   PubMed Web of Science ®Google Scholar
• Smithson M, Irwin R, Williams G. 2022. Sialyltransferase ST6GAL-1 mediates resistance to chemoradiation in rectal cancer [published online ahead of print, 2022 Jan 15]. J Biol Chem. 101594. doi:10.1016/j.jbc.2022.101594.
   PubMed Web of Science ®Google Scholar
• Sørensen AL, Reis CA, Tarp MA. 2006. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology. 16(2):96–107. doi:10.1093/glycob/cwj044.
   PubMed Web of Science ®Google Scholar
• Stanczak MA, Siddiqui SS, Trefny MP. 2018. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 128(11):4912–4923. doi:10.1172/JCI120612.
   PubMed Web of Science ®Google Scholar
• Stanley P. 2011. Golgi glycosylation. Cold Spring Harb Perspect Biol. 3(4):a005199. doi:10.1101/cshperspect.a005199.
   PubMed Web of Science ®Google Scholar
• Stegmayr J, Zetterberg F, Carlsson MC. 2019. Extracellular and intracellular small-molecule galectin-3 inhibitors. Sci Rep. 9(1):2186. doi:10.1038/s41598-019-38497-8.
   PubMedGoogle Scholar
• Stencel-Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS. 2014. The sweet spot: defining virus-sialic acid interactions. Nat Rev Microbiol. 12(11):739–749. doi:10.1038/nrmicro3346.
   PubMed Web of Science ®Google Scholar
• St-Gelais J, Denavit V, Giguère D. 2020. Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement/azidation reaction cascade. Org Biomol Chem. 18(20):3903–3907. doi:10.1039/d0ob00910e.
   PubMed Web of Science ®Google Scholar
• Stimmer L, Dehay S, Nemati F. 2014. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds. BMC Cancer. 14:916. doi:10.1186/1471-2407-14-916.
   PubMed Web of Science ®Google Scholar
• Stokke JL, Bhojwani D. 2021. Antibody-drug conjugates for the treatment of acute pediatric leukemia. J Clin Med. 10(16):3556. doi:10.3390/jcm10163556.
   PubMed Web of Science ®Google Scholar
• Stowell SR, Ju T, Cummings RD. 2015. Protein glycosylation in cancer. Annu Rev Pathol. 10:473–510. doi:10.1146/annurev-pathol-012414-040438.
   PubMed Web of Science ®Google Scholar
• Strohl WR, Naso M. 2019. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies. 8(3):41. doi:10.3390/antib8030041.
   Web of Science ®Google Scholar
• Sun S, Hao H, Yang G, Zhang Y, Fu Y. 2018. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018:2386187. doi:10.1155/2018/2386187.
   PubMed Web of Science ®Google Scholar
• Swanson MD, Boudreaux DM, Salmon L. 2015. Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell. 163(3):746–758. doi:10.1016/j.cell.2015.09.056.
   PubMed Web of Science ®Google Scholar
• Świerzko AS, Cedzyński M. 2020. The influence of the Lectin pathway of complement activation on infections of the respiratory system. Front Immunol. 11:585243. doi:10.3389/fimmu.2020.585243.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Moyo P, Chigweshe L, Chang WC, White MR, Hartshorn KL. 2013. Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res. 178(2):495–501. doi:10.1016/j.virusres.2013.10.001.
   PubMed Web of Science ®Google Scholar
• Tanaka T. 2016. Leukocyte adhesion molecules. In: Michael J.H. Ratcliffe, editor. Encyclopedia of immunobiology. Academic Press; p. 505–511. doi:10.1016/B978-0-12-374279-7.07015-6
   Google Scholar
• Tang J, Lin G, Langdon WY, Tao L, Zhang J. 2018. Regulation of C-type lectin receptor-mediated antifungal immunity. Front Immunol. 9:123. doi:10.3389/fimmu.2018.00123.
   PubMed Web of Science ®Google Scholar
• Tang L, Zhang Y, Hu Y, Mei H. 2021. T cell exhaustion and CAR-T immunotherapy in hematological malignancies. Biomed Res Int. 2021:6616391. doi:10.1155/2021/6616391.
   PubMed Web of Science ®Google Scholar
• Tang XL, Yuan CH, Ding Q, Zhou Y, Pan Q, Zhang XL. 2017. Selection and identification of specific glycoproteins and glycan biomarkers of macrophages involved in Mycobacterium tuberculosis infection. Tuberculosis. 104:95–106. doi:10.1016/j.tube.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Taniguchi N, Kizuka Y. 2015. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv Cancer Res. 126:11–51. doi:10.1016/bs.acr.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Taniguchi N, Miyoshi E, Ko JH, Ikeda Y, Ihara Y. 1999. Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochim Biophys Acta. 1455(2–3):287–300. doi:10.1016/s0925-4439(99)00066-6.
   PubMed Web of Science ®Google Scholar
• Tashiro H, Sauer T, Shum T. 2017. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther. 25(9):2202–2213. doi:10.1016/j.ymthe.2017.05.024.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Hunger SP. 2017. Targeted therapy and precision medicine. Childhood acute lymphoblastic leukemia.
   Google Scholar
• Teachey DT, Pui CH. 2019. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 20(3):e142–e154. doi:10.1016/S1470-2045(19)30031-2.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL. 2013. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121(26):5154–5157. doi:10.1182/blood-2013-02-485623.
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R, Militi S. 2002. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 100(8):2980–2988. doi:10.1182/blood-2002-03-0852.
   PubMed Web of Science ®Google Scholar
• Thielens NM, Cseh S, Thiel S. 2001. Interaction properties of human mannan-binding lectin (MBL)-associated serine proteases-1 and -2, MBL-associated protein 19, and MBL. J Immunol. 166(8):5068–5077. doi:10.4049/jimmunol.166.8.5068.
   PubMed Web of Science ®Google Scholar
• Thomas X. 2014. Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia. Blood Lymphat Cancer. 4:1–8. doi:10.2147/BLCTT.S49048.
   Google Scholar
• Thurin M. 2021. Tumor-associated glycans as targets for immunotherapy: the Wistar institute experience/legacy. Monoclon Antib Immunodiagn Immunother. 40(3):89–100. doi:10.1089/mab.2021.0024.
   PubMedGoogle Scholar
• Topp MS, Gökbuget N, Stein AS. 2015. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study [published correction appears in Lancet Oncol. 2015 Apr;16(4):e158]. Lancet Oncol. 16(1):57–66. doi:10.1016/S1470-2045(14)71170-2.
   PubMed Web of Science ®Google Scholar
• Townsend MH, Shrestha G, Robison RA, O’Neill KL. 2018. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res. 37(1):163. doi:10.1186/s13046-018-0817-0.
   PubMedGoogle Scholar
• Trabbic KR, Kleski KA, Barchi JJ. 2021. A stable gold nanoparticle-based vaccine for the targeted delivery of tumor-associated glycopeptide antigens. ACS Bio Med Chem Au. 1(1):31–43. doi:10.1021/acsbiomedchemau.1c00021.
   PubMedGoogle Scholar
• Trinchera M, Aronica A, Dall’Olio F. 2017. Selectin ligands Sialyl-Lewis a and Sialyl-Lewis x in gastrointestinal cancers. Biology. 6(1):16. doi:10.3390/biology6010016.
   PubMed Web of Science ®Google Scholar
• Tsaneva M, Van Damme EJM. 2020. 130 years of plant lectin research. Glycoconj J. 37(5):533–551. doi:10.1007/s10719-020-09942-y.
   PubMed Web of Science ®Google Scholar
• Tsuboi S, Sutoh M, Hatakeyama S. 2011. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30(15):3173–3185. doi:10.1038/emboj.2011.215.
   PubMed Web of Science ®Google Scholar
• Turzanski J, Grundy M, Shang S, Russell N, Pallis M. 2005. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol. 33(1):62–72. doi:10.1016/j.exphem.2004.10.005.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. 2019. FDA approves crizanlizumab-tmca for sickle cell disease. FDA.
   Google Scholar
• Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. 2011. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 118(19):5084–5095. doi:10.1182/blood-2011-07-365817.
   PubMed Web of Science ®Google Scholar
• Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, et al. 2021. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 137(6):751–762. doi:10.1182/blood.2020007732.
   PubMed Web of Science ®Google Scholar
• Vajaria BN, Patel PS. 2017. Glycosylation: a hallmark of cancer? Glycoconj J. 34(2):147–156. doi:10.1007/s10719-016-9755-2.
   PubMed Web of Science ®Google Scholar
• van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. 2009. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer. 9:180. doi:10.1186/1471-2407-9-180.
   PubMed Web of Science ®Google Scholar
• Vandamme-Feldhaus V, Schauer R. 1998. Characterization of the enzymatic 7-O-acetylation of sialic acids and evidence for enzymatic O-acetyl migration from C-7 to C-9 in bovine submandibular gland. J Biochem. 124(1):111–121. doi:10.1093/oxfordjournals.jbchem.a022069.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324(5930):1029–1033. doi:10.1126/science.1160809.
   PubMed Web of Science ®Google Scholar
• van de Wall S, Santegoets KCM, van Houtum EJH, Büll C, Adema GJ. 2020. Sialoglycans and Siglecs can shape the tumor immune microenvironment. Trends Immunol. 41(4):274–285. doi:10.1016/j.it.2020.02.001.
   PubMed Web of Science ®Google Scholar
• van Elsas MJ, van Hall T, van der Burg SH. 2020. Future challenges in cancer resistance to immunotherapy. Cancers. 12(4):935. doi:10.3390/cancers12040935.
   PubMed Web of Science ®Google Scholar
• van Houtum EJH, Büll C, Cornelissen LAM, Adema GJ. 2021. Siglec signaling in the tumor microenvironment. Front Immunol. 12:790317. doi:10.3389/fimmu.2021.790317.
   PubMed Web of Science ®Google Scholar
• van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. 2006. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 12(13):4027–4035. doi:10.1158/1078-0432.CCR-06-0066.
   PubMed Web of Science ®Google Scholar
• Varambally S, Bar-Dayan Y, Bayry J. 2004. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol. 16(3):517–524. doi:10.1093/intimm/dxh053.
   PubMed Web of Science ®Google Scholar
• Varki A. 2001. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol. 33:54–69. doi:10.1002/ajpa.10018.abs.
   PubMedGoogle Scholar
• Varki A. 2008. Sialic acids in human health and disease. Trends Mol Med. 14(8):351–360. doi:10.1016/j.molmed.2008.06.002.
   PubMed Web of Science ®Google Scholar
• Varki A. 2017. Biological roles of glycans. Glycobiology. 27(1):3–49. doi:10.1093/glycob/cww086.
   PubMed Web of Science ®Google Scholar
• Varki A, Cummings RD, Aebi M. 2015a. Symbol nomenclature for graphical representations of glycans. Glycobiology. 25(12):1323–1324. doi:10.1093/glycob/cwv091.
   PubMed Web of Science ®Google Scholar
• Varki A, Etzler ME, Cummings RD, Esko JD. 2009. Discovery and classification of glycan-binding proteins. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of glycobiology. Chapter 26. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press. https://www.ncbi.nlm.nih.gov/books/NBK1923/.
   Google Scholar
• Varki A, Kannagi R, Toole B. 2015b. Glycosylation changes in cancer. In: Varki A, Cummings RD, Esko JD, editor. Essentials of glycobiology. Harbor: Cold Spring; p. 597–609.
   Google Scholar
• Varki A, Schauer R. 2009. Sialic acids. In: Varki A, Cummings RD, Esko JD, et al., editor. Essentials of glycobiology. Chapter 14. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press. https://www.ncbi.nlm.nih.gov/books/NBK1920/.
   Google Scholar
• Varki A, Schnaar RL, Schauer R. 2017. Sialic acids and other nonulosonic acids. In: Varki A, Cummings RD, Esko JD, editor. Essentials of glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; p. 2015–2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK453082/. doi:10.1101/glycobiology.3e.015
   Google Scholar
• Vasta GR, Feng C, González-Montalbán N. 2017. Functions of galectins as ‘self/non-self’-recognition and effector factors. Pathog Dis. 75(5):ftx046. doi:10.1093/femspd/ftx046.
   PubMed Web of Science ®Google Scholar
• Veerman AJ, Hogeman PH, Huismans DR, Van Zantwijk CH, Bezemer PD. 1985. Peanut agglutinin, a marker for T-cell acute lymphoblastic leukemia with a good prognosis. Cancer Res. 45(4):1890–1893.
   PubMed Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J. 2011. High levels of CD34+CD38low/-CD123+blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 96(12):1792–1798. doi:10.3324/haematol.2011.047894.
   PubMed Web of Science ®Google Scholar
• Vimr ER, Kalivoda KA, Deszo EL, Steenbergen SM. 2004. Diversity of microbial sialic acid metabolism. Microbiol Mol Biol Rev. 68(1):132–153. doi:10.1128/MMBR.68.1.132-153.2004.
   PubMed Web of Science ®Google Scholar
• Visser EA, Moons SJ, Timmermans SBPE, de Jong H, Boltje TJ, Büll C. 2021. Sialic acid O-acetylation: from biosynthesis to roles in health and disease. J Biol Chem. 297(2):100906. doi:10.1016/j.jbc.2021.100906.
   PubMed Web of Science ®Google Scholar
• Vlad AM, Muller S, Cudic M. 2002. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med. 196(11):1435–1446. doi:10.1084/jem.20020493.
   PubMed Web of Science ®Google Scholar
• Vollmers HP, Brändlein S. 2009. Natural antibodies and cancer. N Biotechnol. 25(5):294–298. doi:10.1016/j.nbt.2009.03.016.
   PubMed Web of Science ®Google Scholar
• von Itzstein M. 2007. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 6(12):967–974. doi:10.1038/nrd2400.
   PubMed Web of Science ®Google Scholar
• Vorup-Jensen T, Petersen SV, Hansen AG. 2000. Distinct pathways of mannan-binding lectin (MBL)- and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2. J Immunol. 165(4):2093–2100. doi:10.4049/jimmunol.165.4.2093.
   PubMed Web of Science ®Google Scholar
• Vorup-Jensen T, Sørensen ES, Jensen UB. 2001. Recombinant expression of human mannan-binding lectin. Int Immunopharmacol. 1(4):677–687. doi:10.1016/s1567-5769(00)00052-7.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. 2020. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 20(11):651–668. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Walter RB. 2014. The role of CD33 as therapeutic target in acute myeloid leukemia. Expert Opin Ther Targets. 18(7):715–718. doi:10.1517/14728222.2014.909413.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VH. 2007. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 109(10):4168–4170. doi:10.1182/blood-2006-09-047399.
   PubMed Web of Science ®Google Scholar
• Walz G, Aruffo A, Kolanus W, Bevilacqua M, Seed B. 1990. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science. 250(4984):1132–1135. doi:10.1126/science.1701275.
   PubMed Web of Science ®Google Scholar
• Wang B, Yang C, Jin X. 2020. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen. MAbs. 12(1):1690959. doi:10.1080/19420862.2019.1690959.
   PubMed Web of Science ®Google Scholar
• Wang D, Wu L, Liu X. 2017. Glycan markers as potential immunological targets in circulating tumor cells. Adv Exp Med Biol. 994:275–284. doi:10.1007/978-3-319-55947-6_15.
   PubMed Web of Science ®Google Scholar
• Wang DY, Johnson DB, Davis EJ. 2018. Toxicities associated With PD-1/PD-L1 blockade. Cancer J. 24(1):36–40. doi:10.1097/PPO.0000000000000296.
   PubMed Web of Science ®Google Scholar
• Wang QS, Wang Y, Lv HY. 2015b. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 23(1):184–191. doi:10.1038/mt.2014.164.
   PubMed Web of Science ®Google Scholar
• Wang W, Li Q, Wu J. 2021. Lentil lectin derived from Lens culinaris exhibit broad antiviral activities against SARS-CoV-2 variants. Emerg Microbes Infect. 10(1):1519–1529. doi:10.1080/22221751.2021.1957720.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fukuda T, Isaji T. 2015a. Loss of α1,6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways. FASEB J. 29(8):3217–3227. doi:10.1096/fj.15-270710.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Z, Li B, Wang S, Chen T, Ye Z. 2019. Innate immune cells: a potential and promising cell population for treating osteosarcoma. Front Immunol. 10:1114. doi:10.3389/fimmu.2019.01114.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Bowden TA, Wilson IA, Crispin M. 2019. Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta Gen Subj. 1863(10):1480–1497. doi:10.1016/j.bbagen.2019.05.012.
   PubMed Web of Science ®Google Scholar
• Wdowiak K, Francuz T, Gallego-Colon E. 2018. Galectin targeted therapy in oncology: current knowledge and perspectives. Int J Mol Sci. 19(1):210. doi:10.3390/ijms19010210.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. 2010. Rituximab: mechanism of action. Semin Hematol. 47(2):115–123. doi:10.1053/j.seminhematol.2010.01.011.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. 2010. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 10(5):317–327. doi:10.1038/nri2744.
   PubMed Web of Science ®Google Scholar
• Werther JL, Tatematsu M, Klein R. 1996. Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Int J Cancer. 69(3):193–199. doi:10.1002/(SICI)1097-0215(19960621)69:3<193::AID-IJC8>3.0.CO;2-V.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. 2015. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15(8):486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Wielgat P, Rogowski K, Niemirowicz-Laskowska K, Car H. 2020. Sialic acid-Siglec axis as molecular checkpoints targeting of immune system: smart players in pathology and conventional therapy. Int J Mol Sci. 21(12):4361. doi:10.3390/ijms21124361.
   PubMed Web of Science ®Google Scholar
• Wiersma VR, de Bruyn M, Helfrich W, Bremer E. 2013. Therapeutic potential of galectin-9 in human disease. Med Res Rev. 33(Suppl. 1):E102–E126. doi:10.1002/med.20249.
   PubMedGoogle Scholar
• Willasch AM, Salzmann-Manrique E, Krenn T. 2017. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience. Bone Marrow Transplant. 52(2):201–208. doi:10.1038/bmt.2016.224.
   PubMed Web of Science ®Google Scholar
• Winkler IG, Barbier V, Nowlan B. 2012. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 18(11):1651–1657. doi:10.1038/nm.2969.
   PubMed Web of Science ®Google Scholar
• Wolchok J. 2018. Putting the immunologic brakes on cancer. Cell. 175(6):1452–1454. doi:10.1016/j.cell.2018.11.006.
   PubMed Web of Science ®Google Scholar
• Wong HK, Wilson AJ, Gibson HM. 2006. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides – cutaneous T cell lymphoma. J Invest Dermatol. 126(1):212–219. doi:10.1038/sj.jid.5700029.
   PubMed Web of Science ®Google Scholar
• Wu SC, Paul A, Ho A. 2021. Generation and use of recombinant galectins. Curr Protoc. 1(3):e63. doi:10.1002/cpz1.63.
   PubMedGoogle Scholar
• Xerri L, Devilard E, Hassoun J, Olive D, Birg F. 1997. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J Pathol. 183(2):182–187. doi:10.1002/(SICI)1096-9896(199710)183:2<182::AID-PATH918>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• Xie P, Shen YF, Shi YP. 2008. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res. 32(3):475–480. doi:10.1016/j.leukres.2007.07.006.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang P, Zhang K, Huang C. 2021. The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. Biochim Biophys Acta Rev Cancer. 1876(2):188634. doi:10.1016/j.bbcan.2021.188634.
   PubMed Web of Science ®Google Scholar
• Yamada K, Mitsui Y, Kakoi N, Kinoshita M, Hayakawa T, Kakehi K. 2012. One-pot characterization of cancer cells by the analysis of mucin-type glycans and glycosaminoglycans. Anal Biochem. 421(2):595–606. doi:10.1016/j.ab.2011.12.017.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Shiozaki K, Moriya S. 2012. Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase. PLoS One. 7(7):e41132. doi:10.1371/journal.pone.0041132.
   PubMed Web of Science ®Google Scholar
• Yamashiro S, Ruan S, Furukawa K. 1993. Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines. Cancer Res. 53(22):5395–5400.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Galluzzi L. 2017. Blinatumomab bridges the gap between leukemia and immunity. Oncoimmunology. 6(11):e1358335. doi:10.1080/2162402X.2017.1358335.
   PubMed Web of Science ®Google Scholar
• Yan X, Lin Y, Liu S, Aziz F, Yan Q. 2015. Fucosyltransferase IV (FUT4) as an effective biomarker for the diagnosis of breast cancer. Biomed Pharmacother. 70:299–304. doi:10.1016/j.biopha.2014.12.048.
   PubMed Web of Science ®Google Scholar
• Yanada M, Konuma T, Yamasaki S. 2021. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 56(5):1126–1133. doi:10.1038/s41409-020-01163-z.
   PubMed Web of Science ®Google Scholar
• Yanada M, Takami A, Yamasaki S. 2020. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. Ann Hematol. 99(6):1351–1360. doi:10.1007/s00277-020-04051-0.
   PubMed Web of Science ®Google Scholar
• Yang JM, Byrd JC, Siddiki BB. 1994. Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology. 4(6):873–884. doi:10.1093/glycob/4.6.873.
   PubMed Web of Science ®Google Scholar
• Yang WH, Nussbaum C, Grewal PK, Marth JD, Sperandio M. 2012. Coordinated roles of ST3Gal-VI and ST3Gal-IV sialyltransferases in the synthesis of selectin ligands. Blood. 120(5):1015–1026. doi:10.1182/blood-2012-04-424366.
   PubMed Web of Science ®Google Scholar
• Yao Y, Li F, Huang J, Jin J, Wang H. 2021. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol. 10(1):39. doi:10.1186/s40164-021-00233-2.
   PubMed Web of Science ®Google Scholar
• Yeh SC, Wang PY, Lou YW. 2016. Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity. Proc Natl Acad Sci USA. 113(20):5592–5597. doi:10.1073/pnas.1604721113.
   PubMed Web of Science ®Google Scholar
• Yi B, Zhang M, Schwartz-Albiez R, Cao Y. 2011. Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells. Int J Oncol. 38(6):1565–1573. doi:10.3892/ijo.2011.992.
   PubMed Web of Science ®Google Scholar
• Yoneyama T, Ohyama C, Hatakeyama S. 2014. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun. 448(4):390–396. doi:10.1016/j.bbrc.2014.04.107.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. 2001. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61(10):4244–4252.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kawaguchi H, Sato S, Ueda R, Furukawa K. 2002. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res. 93(7):816–824. doi:10.1111/j.1349-7006.2002.tb01324.x.
   PubMedGoogle Scholar
• Yurkiewicz IR, Muffly L, Liedtke M. 2018. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Drug Des Devel Ther. 12:2293–2300. doi:10.2147/DDDT.S150317.
   PubMed Web of Science ®Google Scholar
• Zajonc DM, Kronenberg M. 2009. Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells. Immunol Rev. 230(1):188–200. doi:10.1111/j.1600-065X.2009.00802.x.
   PubMedGoogle Scholar
• Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M. 2007. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol. 150(3):576–584. doi:10.1111/j.1365-2249.2007.03507.x.
   PubMed Web of Science ®Google Scholar
• Zhan L, Chen L, Chen Z. 2018. Knockdown of FUT3 disrupts the proliferation, migration, tumorigenesis and TGF-β induced EMT in pancreatic cancer cells. Oncol Lett. 16(1):924–930. doi:10.3892/ol.2018.8738.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang G, Hayden MS. 2004. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 303(5663):1522–1526. doi:10.1126/science.1094351.
   PubMed Web of Science ®Google Scholar
• Zhang W, Peumans WJ, Barre A. 2000. Isolation and characterization of a jacalin-related mannose-binding lectin from salt-stressed rice (Oryza sativa) plants. Planta. 210(6):970–978. doi:10.1007/s004250050705.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. 2020. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 8:17. doi:10.3389/fcell.2020.00017.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wuhrer M, Holst S. 2018. Serum sialylation changes in cancer. Glycoconj J. 35(2):139–160. doi:10.1007/s10719-018-9820-0.
   PubMed Web of Science ®Google Scholar
• Zhao J, Simeone DM, Heidt D, Anderson MA, Lubman DM. 2006. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res. 5(7):1792–1802. doi:10.1021/pr060034r.
   PubMed Web of Science ®Google Scholar
• Zhao X, Singh S, Pardoux C. 2010. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica. 95(1):71–78. doi:10.3324/haematol.2009.009811.
   PubMed Web of Science ®Google Scholar
• Zheng B, Yu SF, Del Rosario G. 2019b. An anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia. Clin Cancer Res. 25(4):1358–1368. doi:10.1158/1078-0432.CCR-18-0333.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Feng W, Wang YJ, Sun Y, Shi G, Yu Q. 2019a. Galectins as potential emerging key targets in different types of leukemia. Eur J Pharmacol. 844:73–78. doi:10.1016/j.ejphar.2018.11.019.
   PubMed Web of Science ®Google Scholar
• Zhou H, Li Y, Liu B. 2017. Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene. 626:106–118. doi:10.1016/j.gene.2017.05.030.
   PubMed Web of Science ®Google Scholar
• Zhou X, Hu W, Qin X. 2008. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. 13(9):954–966. doi:10.1634/theoncologist.2008-0089.
   PubMed Web of Science ®Google Scholar
• Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. 2005. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol. 35(7):2175–2183. doi:10.1002/eji.200425920.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Reinhardt D, Jürgens H. 2003. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia. 17(2):468–470. doi:10.1038/sj.leu.2402749.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Reinhardt D, Zimmerman M. 2010. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 148(5):768–776. doi:10.1111/j.1365-2141.2009.08011.x.
   PubMed Web of Science ®Google Scholar